<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with OASIS Tables with MathML3 v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archive-oasis-article1-mathml3.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jpoasis-nisons2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><front><journal-meta><journal-id journal-id-type="nlm-ta">Rev Med Virol</journal-id><journal-id journal-id-type="iso-abbrev">Rev. Med. Virol</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)1099-1654</journal-id><journal-id journal-id-type="publisher-id">RMV</journal-id><journal-title-group><journal-title>Reviews in Medical Virology</journal-title></journal-title-group><issn pub-type="ppub">1052-9276</issn><issn pub-type="epub">1099-1654</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7435512</article-id><article-id pub-id-type="doi">10.1002/rmv.2143</article-id><article-id pub-id-type="publisher-id">RMV2143</article-id><article-categories><subj-group subj-group-type="overline"><subject>Review</subject></subj-group><subj-group subj-group-type="heading"><subject>Reviews</subject></subj-group></article-categories><title-group><article-title>Drugs against <styled-content style="fixed-case" toggle="no">SARS&#x02010;CoV</styled-content>&#x02010;2: What do we know about their mode of action?</article-title><alt-title alt-title-type="left-running-head">Valle et al.</alt-title></title-group><contrib-group><contrib id="rmv2143-cr-0001" contrib-type="author"><name><surname>Valle</surname><given-names>Coralie</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-3497-5378</contrib-id><xref ref-type="aff" rid="rmv2143-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="rmv2143-cr-0002" contrib-type="author"><name><surname>Martin</surname><given-names>Baptiste</given-names></name><xref ref-type="aff" rid="rmv2143-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="rmv2143-cr-0003" contrib-type="author"><name><surname>Touret</surname><given-names>Franck</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-4734-2249</contrib-id><xref ref-type="aff" rid="rmv2143-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="rmv2143-cr-0004" contrib-type="author"><name><surname>Shannon</surname><given-names>Ashleigh</given-names></name><xref ref-type="aff" rid="rmv2143-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="rmv2143-cr-0005" contrib-type="author"><name><surname>Canard</surname><given-names>Bruno</given-names></name><xref ref-type="aff" rid="rmv2143-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="rmv2143-cr-0006" contrib-type="author"><name><surname>Guillemot</surname><given-names>Jean&#x02010;Claude</given-names></name><xref ref-type="aff" rid="rmv2143-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="rmv2143-cr-0007" contrib-type="author" corresp="yes"><name><surname>Coutard</surname><given-names>Bruno</given-names></name><xref ref-type="aff" rid="rmv2143-aff-0003">
<sup>3</sup>
</xref><address><email>bruno.coutard@univ-amu.fr</email></address></contrib><contrib id="rmv2143-cr-0008" contrib-type="author" corresp="yes"><name><surname>Decroly</surname><given-names>Etienne</given-names></name><xref ref-type="aff" rid="rmv2143-aff-0001">
<sup>1</sup>
</xref><address><email>etienne.decroly@afmb.univ-mrs.fr</email></address></contrib></contrib-group><aff id="rmv2143-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Laboratoire AFMB</named-content>
<institution>Aix Marseille Universit&#x000e9;, CNRS, UMR 7257</institution>
<city>Marseille</city>
<country country="FR">France</country>
</aff><aff id="rmv2143-aff-0002">
<label><sup>2</sup></label>
<institution>Beyond Humanity</institution>
<city>Lyon</city>
<country country="FR">France</country>
</aff><aff id="rmv2143-aff-0003">
<label><sup>3</sup></label>
<institution>Unit&#x000e9; des Virus Emergents (UVE: Aix Marseille Univ, IRD 190, INSERM 1207, IHU M&#x000e9;diterran&#x000e9;e Infection)</institution>
<city>Marseille</city>
<country country="FR">France</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Bruno Coutard, Unit&#x000e9; des Virus Emergents (UVE: Aix Marseille Univ, IRD 190, INSERM 1207, IHU M&#x000e9;diterran&#x000e9;e Infection), 13005 Marseille, France.<break/>
Email: <email>bruno.coutard@univ-amu.fr</email><break/>
Etienne Decroly, Laboratoire AFMB, Aix Marseille Univ, CNRS, UMR 7257, Marseille, France.<break/>
Email: <email>etienne.decroly@afmb.univ-mrs.fr</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>11</day><month>8</month><year>2020</year></pub-date><elocation-id>e2143</elocation-id><history><date date-type="received"><day>19</day><month>5</month><year>2020</year></date><date date-type="rev-recd"><day>23</day><month>6</month><year>2020</year></date><date date-type="accepted"><day>24</day><month>6</month><year>2020</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2020 John Wiley & Sons, Ltd. <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2020 John Wiley &#x00026; Sons, Ltd</copyright-statement><license><license-p>This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="file:RMV-9999-e2143.pdf"/><abstract><title>Summary</title><p>The health emergency caused by the recent Covid&#x02010;19 pandemic highlights the need to identify effective treatments against the virus causing this disease (SARS&#x02010;CoV&#x02010;2). The first clinical trials have been testing repurposed drugs that show promising anti&#x02010;SARS&#x02010;CoV&#x02010;2 effects in cultured cells. Although more than 2400 clinical trials are already under way, the actual number of tested compounds is still limited to approximately 20, alone or in combination. In addition, knowledge on their mode of action (MoA) is currently insufficient. Their first results reveal some inconsistencies and contradictory results and suggest that cohort size and quality of the control arm are two key issues for obtaining rigorous and conclusive results. Moreover, the observed discrepancies might also result from differences in the clinical inclusion criteria, including the possibility of early treatment that may be essential for therapy efficacy in patients with Covid&#x02010;19. Importantly, efforts should also be made to test new compounds with a documented MoA against SARS&#x02010;CoV&#x02010;2 in clinical trials. Successful treatment will probably be based on multitherapies with antiviral compounds that target different steps of the virus life cycle. Moreover, a multidisciplinary approach that combines artificial intelligence, compound docking, and robust in&#x02009;vitro and in&#x02009;vivo assays will accelerate the development of new antiviral molecules. Finally, large retrospective studies on hospitalized patients are needed to evaluate the different treatments with robust statistical tools and to identify the best treatment for each Covid&#x02010;19 stage. This review describes different candidate antiviral strategies for Covid&#x02010;19, by focusing on their mechanism of action.</p></abstract><abstract abstract-type="highlights"><title>Highlights</title><p>
<list list-type="bullet" id="rmv2143-list-0001"><list-item id="rmv2143-li-0001"><p>SARS&#x02010;CoV&#x02010;2 is a major threat to public health in the absence of drugs and vaccines.</p></list-item><list-item id="rmv2143-li-0002"><p>The development of antiviral agents is urgently needed to treat patients with Covid&#x02010;19 and limit SARS&#x02010;CoV&#x02010;2 dissemination.</p></list-item><list-item id="rmv2143-li-0003"><p>Several studies identified compounds that limit SARS&#x02010;CoV&#x02010;2 replication in&#x02009;vitro and determined the mode of action of some promising antiviral drugs.</p></list-item><list-item id="rmv2143-li-0004"><p>Drug repurposing for Covid&#x02010;19 treatment is in progress, and the mode of action of these compounds needs to be clarified.</p></list-item></list>
</p></abstract><funding-group><award-group id="funding-0001"><funding-source>European Union's Horizon 2020 research and innovation programme</funding-source><award-id>101003627</award-id></award-group><award-group id="funding-0002"><funding-source>SCORE project H2020 SC1&#x02010;PHE&#x02010;Coronavirus194 2020</funding-source><award-id>101003627</award-id></award-group><award-group id="funding-0003"><funding-source><institution-wrap><institution>Fondation pour la Recherche M&#x000e9;dicale </institution><institution-id institution-id-type="open-funder-registry">10.13039/501100002915</institution-id></institution-wrap></funding-source></award-group><award-group id="funding-0004"><funding-source><institution-wrap><institution>Inserm </institution><institution-id institution-id-type="open-funder-registry">10.13039/501100001677</institution-id></institution-wrap></funding-source></award-group></funding-group><counts><fig-count count="1"/><table-count count="2"/><page-count count="10"/><word-count count="9251"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>edited-state</meta-name><meta-value>corrected-proof</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:5.8.7 mode:remove_FC converted:19.08.2020</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="self-citation" id="rmv2143-cit-9001">
<string-name>
<surname>Valle</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Martin</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Touret</surname>
<given-names>F</given-names>
</string-name>, et al. <article-title>Drugs against <styled-content style="fixed-case" toggle="no">SARS&#x02010;CoV</styled-content>&#x02010;2: What do we know about their mode of action?</article-title>
<source xml:lang="en">Rev Med Virol</source>. <year>2020</year>;<elocation-id>e2143</elocation-id>
<pub-id pub-id-type="doi">10.1002/rmv.2143</pub-id>
<pub-id pub-id-type="pmid">32779326</pub-id></mixed-citation>
</p><fn-group><fn id="rmv2143-note-1002"><p>
<bold>Funding information</bold> European Union's Horizon 2020 research and innovation programme, Grant/Award Number: 101003627; SCORE project H2020 SC1&#x02010;PHE&#x02010;Coronavirus194 2020, Grant/Award Number: 101003627; Fondation pour la Recherche M&#x000e9;dicale; Inserm</p></fn></fn-group></notes></front><body id="rmv2143-body-0001"><def-list list-content="abbreviations" id="rmv2143-lp-0001"><title>Abbreviations</title><def-item><term id="rmv2143-li-0005">3CLpro</term><def id="rmv2143-li-0006"><p>chymotrypsin&#x02010;like 3</p></def></def-item><def-item><term id="rmv2143-li-0007">Abs</term><def id="rmv2143-li-0008"><p>antibodies</p></def></def-item><def-item><term id="rmv2143-li-0009">ACE2</term><def id="rmv2143-li-0010"><p>angiotensin&#x02010;converting enzyme 2</p></def></def-item><def-item><term id="rmv2143-li-0011">CoV</term><def id="rmv2143-li-0012"><p>coronaviruses</p></def></def-item><def-item><term id="rmv2143-li-0013">E</term><def id="rmv2143-li-0014"><p>envelope protein</p></def></def-item><def-item><term id="rmv2143-li-0015">ExoN</term><def id="rmv2143-li-0016"><p>exonuclease</p></def></def-item><def-item><term id="rmv2143-li-0017">FDA</term><def id="rmv2143-li-0018"><p>Food and Drug Administration</p></def></def-item><def-item><term id="rmv2143-li-0019">HCQ</term><def id="rmv2143-li-0020"><p>hydroxychloroquine</p></def></def-item><def-item><term id="rmv2143-li-0021">HIV</term><def id="rmv2143-li-0022"><p>human immunodeficiency virus</p></def></def-item><def-item><term id="rmv2143-li-0023">IFN</term><def id="rmv2143-li-0024"><p>interferon</p></def></def-item><def-item><term id="rmv2143-li-0025">IL</term><def id="rmv2143-li-0026"><p>interleukin</p></def></def-item><def-item><term id="rmv2143-li-0027">M</term><def id="rmv2143-li-0028"><p>membrane protein</p></def></def-item><def-item><term id="rmv2143-li-0029">mAbs</term><def id="rmv2143-li-0030"><p>monoclonal Abs</p></def></def-item><def-item><term id="rmv2143-li-0031">MERS</term><def id="rmv2143-li-0032"><p>Middle East respiratory syndrome</p></def></def-item><def-item><term id="rmv2143-li-0033">MoA</term><def id="rmv2143-li-0034"><p>mode of action</p></def></def-item><def-item><term id="rmv2143-li-0035">N</term><def id="rmv2143-li-0036"><p>nucleoprotein</p></def></def-item><def-item><term id="rmv2143-li-0037">nsp</term><def id="rmv2143-li-0038"><p>nonstructural protein</p></def></def-item><def-item><term id="rmv2143-li-0039">PLpro</term><def id="rmv2143-li-0040"><p>papain&#x02010;like</p></def></def-item><def-item><term id="rmv2143-li-0041">RdRp</term><def id="rmv2143-li-0042"><p>RNA&#x02010;dependent RNA polymerase</p></def></def-item><def-item><term id="rmv2143-li-0043">S</term><def id="rmv2143-li-0044"><p>spike protein</p></def></def-item><def-item><term id="rmv2143-li-0045">SARS</term><def id="rmv2143-li-0046"><p>severe acute respiratory syndrome</p></def></def-item><def-item><term id="rmv2143-li-0047">TMPRSS2</term><def id="rmv2143-li-0048"><p>transmembrane protease serine 2</p></def></def-item></def-list><sec id="rmv2143-sec-0001"><label>1</label><title>INTRODUCTION TO <styled-content style="fixed-case" toggle="no">SARS&#x02010;CORONAVIRUS</styled-content> 2</title><p>Over the last 20&#x02009;years, three coronaviruses (CoVs) that cause severe pulmonary infections in humans have crossed the species barrier.<xref rid="rmv2143-bib-0001" ref-type="ref">
<sup>1</sup>
</xref>, <xref rid="rmv2143-bib-0002" ref-type="ref">
<sup>2</sup>
</xref> The last of these CoVs, named SARS&#x02010;CoV&#x02010;2, emerged in the Hubei province (China) in December 2019, and rapidly spread worldwide becoming a major public health threat.<xref rid="rmv2143-bib-0003" ref-type="ref">
<sup>3</sup>
</xref> In approximately 20% of patients, the disease progresses to severe pneumonia, respiratory and multi&#x02010;visceral failure, often leading to death of patients with comorbidity.<xref rid="rmv2143-bib-0004" ref-type="ref">
<sup>4</sup>
</xref> This worsening is associated with a deregulated immune response, including exacerbated production of pro&#x02010;inflammatory cytokines.<xref rid="rmv2143-bib-0005" ref-type="ref">
<sup>5</sup>
</xref> Therefore, specific and effective antiviral therapies are urgently needed, due to the absence of a vaccine.</p><p>Coronaviruses belong to the <italic>Nidovirales</italic> order, a group of enveloped viruses with genomic RNA of positive polarity. Their 27 to 34&#x02009;kb genome encodes 16 nonstructural proteins (nsps) and 4 structural proteins (spike protein [S], envelope protein [E], membrane protein [M], and nucleoprotein [N]).<xref rid="rmv2143-bib-0006" ref-type="ref">
<sup>6</sup>
</xref> The virus life cycle, described in Figure <xref rid="rmv2143-fig-0001" ref-type="fig">1</xref>, begins by the attachment of the viral particle to the angiotensin&#x02010;converting enzyme 2 (ACE2) cell surface receptor, mediated by the S protein.<xref rid="rmv2143-bib-0007" ref-type="ref">
<sup>7</sup>
</xref>, <xref rid="rmv2143-bib-0008" ref-type="ref">
<sup>8</sup>
</xref> Virus entry is achieved by endocytosis and/or direct fusion of the cell and viral membranes. This step requires S protein activation. The S protein is synthesized as an inactive precursor that is inserted in the viral membrane, and requires two subsequent cleavages by cellular proteases to become functionally active. Different cellular proteases, such as furin&#x02010;like enzymes and the transmembrane protease serine 2 (TMPRSS2), may cleave the S protein in two subunits, S1 and S2, in a process called &#x0201c;priming.&#x0201d;<xref rid="rmv2143-bib-0009" ref-type="ref">
<sup>9</sup>
</xref>, <xref rid="rmv2143-bib-0010" ref-type="ref">
<sup>10</sup>
</xref> A recent study showed that this furin&#x02010;mediated cleavage is important for virus entry in lung cells.<xref rid="rmv2143-bib-0011" ref-type="ref">
<sup>11</sup>
</xref> In addition, for virus entry, a second proteolytic cleavage is required at the S2&#x02032; site localized immediately upstream of the fusion peptide,<xref rid="rmv2143-bib-0012" ref-type="ref">
<sup>12</sup>
</xref>, <xref rid="rmv2143-bib-0013" ref-type="ref">
<sup>13</sup>
</xref> and seems to involve at least TMPRSS2.<xref rid="rmv2143-bib-0014" ref-type="ref">
<sup>14</sup>
</xref> The viral genome is then released into the cytoplasm of the infected cells. This allows the translation of the viral mRNA into two polyprotein precursors, pp1a and pp1ab, controlled by a &#x02212;1 ribosomal frameshift. These polyprotein precursors are then cleaved by two viral proteases, chymotrypsin&#x02010;like 3 (3CLpro) and papain&#x02010;like (PLpro), to generate the 16&#x02009;nsps (nsp1 to 16). Many of these proteins participate in the formation of the replication and transcription complex that orchestrates genome replication, mRNA synthesis and capping. At the final stage of viral infection, the N protein assembles with the neo&#x02010;synthesized viral genome to form the nucleocapsid that associates with the viral structural proteins to generate new virions released by exocytosis.<xref rid="rmv2143-bib-0006" ref-type="ref">
<sup>6</sup>
</xref>
</p><fig fig-type="FIGURE" xml:lang="en" id="rmv2143-fig-0001" orientation="portrait" position="float"><label>FIGURE 1</label><caption><p>SARS&#x02010;CoV&#x02010;2 life cycle and potential mechanisms of action of currently evaluated therapeutics. SARS&#x02010;CoV&#x02010;2 life cycle and the presumed mechanisms of action (MoA) of the main SARS&#x02010;CoV&#x02010;2 replication inhibitors. Different compounds are assessed to find compounds targeting the different steps of SARS&#x02010;CoV&#x02010;2 life cycle. Molecules currently in clinical trials are indicated by a gray star. Therapeutic strategies based on antiviral compounds are indicated in red, and approved drugs used for other diseases or selected by virtual screening are indicated in yellow. The black question marks indicate unknown or elusive MoA in the context of CoV infection. *Corresponding to antibody (Ab) strategies including monoclonal antibodies and plasma from convalescent patient. The Biorender website was used to generate this figure</p></caption><graphic id="nlm-graphic-1" xlink:href="RMV-9999-e2143-g001"/></fig><p>The ongoing Covid&#x02010;19 pandemic has already caused at least 4 million confirmed cases and more than 250&#x02009;000 deaths. In response to this global health emergency, public health measures to control the virus spread have been put in place and efforts to identify potential antiviral molecules and to develop a vaccine have been intensified. The explored antiviral strategies are mainly based on existing drugs that were developed to treat viral infection or other diseases. Moreover, the many different clinical trials currently in progress (more than 2400) are testing a limited set of drugs, alone or in combination.<xref rid="rmv2143-bib-0015" ref-type="ref">
<sup>15</sup>
</xref> Although the drugs used in these therapeutic assays have shown some inhibitory effect in SARS&#x02010;CoV&#x02010;2&#x02010;infected cells in&#x02009;vitro, the molecular bases of their antiviral activity are often poorly understood, except for nucleoside analogs (eg, favipiravir for influenza virus) and fusion inhibitors (eg, arbidol). In addition, while waiting for the final results of these clinical studies, important concerns have arisen, such as the risk of inappropriate self&#x02010;treatment, the potential toxicity or adverse effects of some of these compounds, and the risk of depletion of pharmacy stocks needed for the treatment of other pathologies. On the other hand, the emergence of SARS&#x02010;CoV and Middle East respiratory syndrome coronavirus (MERS&#x02010;CoV) has led to a growing number of publications that describe new CoV inhibitors and precisely characterize their mode of action (MoA). In this review, we summarize promising candidate molecules that could be repurposed and anti&#x02010;CoV&#x02010;specific drugs derived from ongoing research on CoVs, for which we provide additional information on their potential MoA based on the current knowledge on SARS&#x02010;COV&#x02010;2 life cycle. In this review, we do not describe vaccine strategies, and supporting treatments, although they are also important for Covid&#x02010;19 management.</p></sec><sec id="rmv2143-sec-0002"><label>2</label><title>CLASSICAL ANTIVIRAL APPROACHES</title><p>In the absence of specific therapeutics, supportive care (eg, oxygen therapy or mechanical ventilation) remains the only option for managing severe Covid&#x02010;19 symptoms.<xref rid="rmv2143-bib-0016" ref-type="ref">
<sup>16</sup>
</xref> To limit virus proliferation in the early disease stages and reduce its severity, one important strategy is to develop treatments based on existing antiviral compounds. Following the rapid emergence and spread of SARS&#x02010;CoV in 2003 and MERS&#x02010;CoV in 2012, important efforts were made to identify drugs that target specific steps of the coronavirus life cycle (Figure <xref rid="rmv2143-fig-0001" ref-type="fig">1</xref>) including (a) the interaction with ACE2 receptors, (b) enzymes that catalyze S protein cleavage, (c) viral entry, (d) polyprotein processing, and (e) replication/transcription complex. These compounds have been rapidly screened in SARS&#x02010;COV&#x02010;2&#x02010;infected cells, and many of them are now assessed in small animal models and/or clinical trials.</p><sec id="rmv2143-sec-0003"><label>2.1</label><title>Antibody neutralization</title><p>A useful therapeutic strategy consists in interfering with the first step of the viral cycle by targeting the interaction of the viral S protein with the cell surface receptors. It was recently demonstrated that sera from patients with Covid&#x02010;19 contain neutralizing antibodies (Abs) that can limit SARS&#x02010;CoV&#x02010;2 viral infection in&#x02009;vitro.<xref rid="rmv2143-bib-0017" ref-type="ref">
<sup>17</sup>
</xref> Moreover, administration of plasma from convalescent patients has shown some efficacy in patients with respiratory distress, suggesting that passive immunity might help limit SARS&#x02010;CoV&#x02010;2 infection.<xref rid="rmv2143-bib-0018" ref-type="ref">
<sup>18</sup>
</xref>, <xref rid="rmv2143-bib-0019" ref-type="ref">
<sup>19</sup>
</xref>, <xref rid="rmv2143-bib-0020" ref-type="ref">
<sup>20</sup>
</xref> Clinical trials using plasmapheresis are under way to evaluate the efficacy of this strategy.<xref rid="rmv2143-bib-0021" ref-type="ref">
<sup>21</sup>
</xref>, <xref rid="rmv2143-bib-0022" ref-type="ref">
<sup>22</sup>
</xref> Nevertheless, recent randomized clinical trial have not shown significant improve for patient under convalescent plasma therapy.<xref rid="rmv2143-bib-0023" ref-type="ref">
<sup>23</sup>
</xref> The development of monoclonal Abs (mAbs) against the viral S protein is also an option.<xref rid="rmv2143-bib-0024" ref-type="ref">
<sup>24</sup>
</xref> This approach was used in the latest Ebola outbreak and led to the development of ZMapp.<xref rid="rmv2143-bib-0025" ref-type="ref">
<sup>25</sup>
</xref> Neutralizing mAbs against the SARS&#x02010; and MERS&#x02010;CoV S protein have antiviral effect in cultured cells and animals infected with SARS&#x02010;CoV or MERS&#x02010;CoV.<xref rid="rmv2143-bib-0026" ref-type="ref">
<sup>26</sup>
</xref>, <xref rid="rmv2143-bib-0027" ref-type="ref">
<sup>27</sup>
</xref>, <xref rid="rmv2143-bib-0028" ref-type="ref">
<sup>28</sup>
</xref>, <xref rid="rmv2143-bib-0029" ref-type="ref">
<sup>29</sup>
</xref>, <xref rid="rmv2143-bib-0030" ref-type="ref">
<sup>30</sup>
</xref> Thus, the development of mAbs targeting the S protein is currently in progress.<xref rid="rmv2143-bib-0031" ref-type="ref">
<sup>31</sup>
</xref> The development of mAbs against ACE2 is also an interesting option to reduce viral entry,<xref rid="rmv2143-bib-0032" ref-type="ref">
<sup>32</sup>
</xref>, <xref rid="rmv2143-bib-0033" ref-type="ref">
<sup>33</sup>
</xref> but could be more risky due to potential interference with the physiological function of the ACE2 receptor, which is involved in angiotensin maturation. Another possibility is to use human recombinant soluble ACE2 to block SARS&#x02010;CoV&#x02010;2 entry into the cell.<xref rid="rmv2143-bib-0034" ref-type="ref">
<sup>34</sup>
</xref> This strategy seems to limit SARS&#x02010;CoV&#x02010;2 infection in cell culture, but the stability of the soluble receptor in the serum of infected patients and the potential adverse effects in patients remain to be determined. Notably, it has also been shown that ACE2 therapy protects mice from lung injury that can be observed during SARS&#x02010;CoV infection.<xref rid="rmv2143-bib-0035" ref-type="ref">
<sup>35</sup>
</xref> Interestingly, mAbs against other cellular receptors, such as CD147, also can block viral infection in cell culture, and the direct interaction between CD147 and the S protein has been demonstrated by coimmunoprecipitation.<xref rid="rmv2143-bib-0036" ref-type="ref">
<sup>36</sup>
</xref> These first results need be confirmed, but they suggest that SARS&#x02010;CoV&#x02010;2 could use an alternative entry receptor in some cell types. A clinical trial using an anti&#x02010;CD147 antibody (meplazumab) is currently ongoing in China<xref rid="rmv2143-bib-0037" ref-type="ref">
<sup>37</sup>
</xref>; however, its antiviral effect is uncertain because the virus binds with higher affinity to the ACE2 receptor.<xref rid="rmv2143-bib-0033" ref-type="ref">
<sup>33</sup>
</xref>
</p></sec><sec id="rmv2143-sec-0004"><label>2.2</label><title>Antiviral molecules</title><p>Although SARS&#x02010;CoV&#x02010;2 has spread very recently, several antiviral compounds previously tested against other pathogenic CoVs have been already tried patients with Covid&#x02010;19 (Table <xref rid="rmv2143-tbl-0001" ref-type="table">1</xref>). The first strategy is to interfere with virus entry using molecules that block virus&#x02010;cell fusion. This includes umifenovir (Arbidol), an antiviral molecule initially developed for the treatment of influenza infection.<xref rid="rmv2143-bib-0062" ref-type="ref">
<sup>62</sup>
</xref> Interestingly, umifenovir has a broad spectrum antiviral activity by inhibiting the entry of other viruses<xref rid="rmv2143-bib-0063" ref-type="ref">
<sup>63</sup>
</xref> and stimulating the immune response.<xref rid="rmv2143-bib-0038" ref-type="ref">
<sup>38</sup>
</xref> Moreover, umifenovir inhibits SARS&#x02010;CoV&#x02010;2 infection in vitro with an IC<sub>50</sub> of 10 &#x003bc;M.<xref rid="rmv2143-bib-0039" ref-type="ref">
<sup>39</sup>
</xref> Although not yet approved by the FDA, this broad&#x02010;spectrum antiviral molecule is used in China and Russia for influenza treatment, and therefore was rapidly included in several clinical trials alone or in combination with other compounds. The first comparative study performed in a small group of patients showed a significant decrease of the viral load in the arm treated with umifenovir in combination with the protease inhibitors lopinavir/ritonavir (n = 16) compared with the arm treated with lopinavir/ritonavir alone (n = 17).<xref rid="rmv2143-bib-0041" ref-type="ref">
<sup>41</sup>
</xref> Nevertheless, one of the limitations of this study is the small&#x02010;sample size and investigation including large cohort need to be performed.</p><table-wrap id="rmv2143-tbl-0001" xml:lang="en" content-type="TABLE" orientation="portrait" position="float"><label>TABLE 1</label><caption><p>Main antiviral molecules currently being tested against SARS&#x02010;CoV&#x02010;2 infection</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Compounds</th><th align="left" valign="bottom" rowspan="1" colspan="1">Target/MoA</th><th align="left" valign="bottom" rowspan="1" colspan="1">Tests in vitro (CoV)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Clinical trials SARS&#x02010;CoV&#x02010;2</th></tr></thead><tbody valign="top"><tr><td align="left" valign="top" rowspan="1" colspan="1">Arbidol hydrochloride</td><td align="left" valign="top" rowspan="1" colspan="1">Endocytosis/inhibition membrane fusion</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="rmv2143-bib-0038" ref-type="ref">38</xref>, <xref rid="rmv2143-bib-0039" ref-type="ref">39</xref>, <xref rid="rmv2143-bib-0040" ref-type="ref">40</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">NCT04252885 (<xref rid="rmv2143-bib-0041" ref-type="ref">41</xref>, <xref rid="rmv2143-bib-0042" ref-type="ref">42</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Ribavirin</td><td align="left" valign="top" rowspan="1" colspan="1">RNA polymerase/inhibition</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="rmv2143-bib-0043" ref-type="ref">43</xref>, <xref rid="rmv2143-bib-0044" ref-type="ref">44</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">No data</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Remdesivir</td><td align="left" valign="top" rowspan="1" colspan="1">RNA polymerase/inhibition</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="rmv2143-bib-0045" ref-type="ref">45</xref>, <xref rid="rmv2143-bib-0046" ref-type="ref">46</xref>, <xref rid="rmv2143-bib-0047" ref-type="ref">47</xref>, <xref rid="rmv2143-bib-0048" ref-type="ref">48</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="rmv2143-bib-0049" ref-type="ref">49</xref>, <xref rid="rmv2143-bib-0050" ref-type="ref">50</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Favipiravir</td><td align="left" valign="top" rowspan="1" colspan="1">RNA polymerase/inhibition</td><td align="left" valign="top" rowspan="1" colspan="1">No data</td><td align="left" valign="top" rowspan="1" colspan="1">ChiCTR2000030894, NCT04280705, NCT04292730, NCT04292899, NCT04315948, WHO Solidarity Trial (<xref rid="rmv2143-bib-0042" ref-type="ref">42</xref>, <xref rid="rmv2143-bib-0051" ref-type="ref">51</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x003b2;&#x02010;d&#x02010;N4&#x02010;hydroxycytidine</td><td align="left" valign="top" rowspan="1" colspan="1">RNA polymerase/inhibition</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="rmv2143-bib-0052" ref-type="ref">52</xref>, <xref rid="rmv2143-bib-0053" ref-type="ref">53</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">No data</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Sofosbuvir</td><td align="left" valign="top" rowspan="1" colspan="1">RNA polymerase/inhibition</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="rmv2143-bib-0054" ref-type="ref">54</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">No data</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x003b1;&#x02010;ketoamide inhibitor</td><td align="left" valign="top" rowspan="1" colspan="1">Proteases/inhibition</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="rmv2143-bib-0055" ref-type="ref">55</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">No data</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Ritonavir</td><td align="left" valign="top" rowspan="1" colspan="1">Proteases/inhibition</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="rmv2143-bib-0056" ref-type="ref">56</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">NCT04252885 (<xref rid="rmv2143-bib-0041" ref-type="ref">41</xref>, <xref rid="rmv2143-bib-0049" ref-type="ref">49</xref>, <xref rid="rmv2143-bib-0057" ref-type="ref">57</xref>, <xref rid="rmv2143-bib-0058" ref-type="ref">58</xref>, <xref rid="rmv2143-bib-0059" ref-type="ref">59</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Lopinavir</td><td align="left" valign="top" rowspan="1" colspan="1">Proteases/inhibition</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="rmv2143-bib-0056" ref-type="ref">56</xref>, <xref rid="rmv2143-bib-0060" ref-type="ref">60</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">NCT04252885 (<xref rid="rmv2143-bib-0041" ref-type="ref">41</xref>, <xref rid="rmv2143-bib-0049" ref-type="ref">49</xref>, <xref rid="rmv2143-bib-0057" ref-type="ref">57</xref>, <xref rid="rmv2143-bib-0058" ref-type="ref">58</xref>, <xref rid="rmv2143-bib-0059" ref-type="ref">59</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Nelfinavir</td><td align="left" valign="top" rowspan="1" colspan="1">Proteases/inhibition</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="rmv2143-bib-0061" ref-type="ref">61</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">No data</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Dolutegravir</td><td align="left" valign="top" rowspan="1" colspan="1">Proteases/inhibition</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="rmv2143-bib-0039" ref-type="ref">39</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">No data</td></tr></tbody></table><table-wrap-foot id="rmv2143-ntgp-0001"><fn id="rmv2143-note-0001"><p>Abbreviations: CoV, coronaviruses; MoA, mode of action.</p></fn></table-wrap-foot></table-wrap><p>After virus entry, the polyproteins pp1a and pp1ab are processed into 16 nsps by the viral proteases 3CLpro and PLpro. These cleavage events play a key role in the virus life cycle because they lead to the generation, among others, of the RNA&#x02010;dependent RNA polymerase (RdRp) required for viral RNA replication and transcription. Due to the high conservation of the cleavage sites and of the protease structures, these proteases are an optimal antiviral target. A recent study described the X&#x02010;ray structures of SARS&#x02010;CoV&#x02010;2 3CLpro alone and in the presence of an &#x003b1;&#x02010;ketoamide inhibitor.<xref rid="rmv2143-bib-0055" ref-type="ref">
<sup>55</sup>
</xref> Based on these findings, the &#x003b1;&#x02010;ketoamide inhibitor was optimized and showed antiviral activity against SARS&#x02010;CoV&#x02010;2 at concentrations lower than 10 &#x003bc;M in Calu3 lung cells. Protease inhibitors used in human immunodeficiency virus (HIV) therapy, such as lopinavir/ritonavir (a combination known as Kaletra), nelfinavir, also limit SARS&#x02010;CoV&#x02010;2 propagation in infected cells,<xref rid="rmv2143-bib-0039" ref-type="ref">
<sup>39</sup>
</xref>, <xref rid="rmv2143-bib-0057" ref-type="ref">
<sup>57</sup>
</xref>, <xref rid="rmv2143-bib-0064" ref-type="ref">
<sup>64</sup>
</xref> and they are being tested in several ongoing clinical trials.<xref rid="rmv2143-bib-0056" ref-type="ref">
<sup>56</sup>
</xref>, <xref rid="rmv2143-bib-0060" ref-type="ref">
<sup>60</sup>
</xref>, <xref rid="rmv2143-bib-0061" ref-type="ref">
<sup>61</sup>
</xref> However, the molecular basis of their inhibition mechanism has not been elucidated yet due to the fact that HIV and CoV proteases belong to different protease classes. Unfortunately, the first clinical trials reported that lopinavir, combined with the ritonavir that boosts lopinavir levels by interfering with cytochrome P450 metabolism, does not have any significant effect on SARS&#x02010;CoV&#x02010;2 infection.<xref rid="rmv2143-bib-0058" ref-type="ref">
<sup>58</sup>
</xref>
</p><p>Historically, the most attractive antiviral compounds are those that block virus replication by inhibiting RdRp activity. Nucleotide and nucleoside analogs are among the most promising groups of RdRp inhibitors. Their antiviral effect can be attributed to three nonmutually exclusive mechanisms. First, incorporation of nucleotide analogs (NAs) in the viral RNA by the error&#x02010;prone polymerase can induce early chain termination in an obligate (immediate) or nonobligate fashion, resulting in incomplete, noninfectious viral RNA. The second mechanism, named error catastrophe, is associated with the insertion and extension of NAs throughout the viral RNA that result in many errors during RNA synthesis.<xref rid="rmv2143-bib-0065" ref-type="ref">
<sup>65</sup>
</xref>, <xref rid="rmv2143-bib-0066" ref-type="ref">
<sup>66</sup>
</xref> Third, several NAs deplete the cytoplasmic levels of their equivalent native nucleotides, causing nucleotide pool imbalances that affect RdRp fidelity.<xref rid="rmv2143-bib-0067" ref-type="ref">
<sup>67</sup>
</xref> While nucleoside analogs have been successfully used for the treatment of other viral diseases, the situation is complicated in CoVs due to the presence of a viral exonuclease (nsp14 ExoN) with proof&#x02010;reading activity that can reduce NA antiviral effect.<xref rid="rmv2143-bib-0068" ref-type="ref">
<sup>68</sup>
</xref>, <xref rid="rmv2143-bib-0069" ref-type="ref">
<sup>69</sup>
</xref> Indeed, in vitro studies show that SARS&#x02010;CoV polymerase can incorporate ribavirin triphosphate during replication, but this purine NA is detected by nsp14 ExoN and eliminated by the repair mechanism.<xref rid="rmv2143-bib-0068" ref-type="ref">
<sup>68</sup>
</xref> This might partly explain the poor antiviral effect of ribavirin in SARS&#x02010; and MERS&#x02010;CoV infection.<xref rid="rmv2143-bib-0043" ref-type="ref">
<sup>43</sup>
</xref>, <xref rid="rmv2143-bib-0070" ref-type="ref">
<sup>70</sup>
</xref> On the other hand, molecules such as remdesivir, initially developed against Ebola virus,<xref rid="rmv2143-bib-0045" ref-type="ref">
<sup>45</sup>
</xref> appear to have an inhibitory effect against SARS&#x02010;CoV and MERS&#x02010;CoV in&#x02009;vitro at the submicro&#x02010; to micromolar range, depending on the infected cell type.<xref rid="rmv2143-bib-0046" ref-type="ref">
<sup>46</sup>
</xref>, <xref rid="rmv2143-bib-0071" ref-type="ref">
<sup>71</sup>
</xref>, <xref rid="rmv2143-bib-0072" ref-type="ref">
<sup>72</sup>
</xref> Remdesivir evaluation in a primate model infected by SARS&#x02010;CoV showed that the antiviral activity is dependent on early treatment after infection.<xref rid="rmv2143-bib-0047" ref-type="ref">
<sup>47</sup>
</xref> Remdesivir is incorporated into nascent RNA by the SARS&#x02010;CoV&#x02010;2 RdRp complex.<xref rid="rmv2143-bib-0054" ref-type="ref">
<sup>54</sup>
</xref> Several clinical trials, such as the European DISCOVERY clinical program,<xref rid="rmv2143-bib-0049" ref-type="ref">
<sup>49</sup>
</xref> are assessing remdesivir safety and efficacy in hospitalized patients with Covid&#x02010;19. The first results of these compassionate&#x02010;use studies showed clinical improvement in 68% of patients treated with remdesivir in a small cohort (n = 53). Notably however, these studies were not randomized and furthermore did not report the change in viral load following treatment.<xref rid="rmv2143-bib-0050" ref-type="ref">
<sup>50</sup>
</xref> While some adverse effects were reported, including abnormal liver function, diarrhea, rashes, renal impairment, and hypotension, remdesivir was licensed in May 2020 as an emergence treatment against SARS&#x02010;CoV&#x02010;2.</p><p>The cytidine analog &#x003b2;&#x02010;d&#x02010;<italic>N</italic>4&#x02010;hydroxycytidine (NHC) also is a potential anti&#x02010;CoV compound. NHC inhibits MERS&#x02010;CoV, SARS&#x02010;CoV, and SARS&#x02010;CoV&#x02010;2 replication in&#x02009;vitro in the micromolar range (0.09&#x02010;0.3 &#x003bc;M), without apparent interference from the viral proofreading activity of nsp14.<xref rid="rmv2143-bib-0052" ref-type="ref">
<sup>52</sup>
</xref> In infected cells, decreased viral replication was associated with increased mutation frequency, supporting a mechanism of lethal mutagenesis. Moreover, the orally bioavailable &#x003b2;&#x02010;D&#x02010;N4&#x02010;hydroxycytidine&#x02010;5&#x02032;&#x02010;isopropyl ester improved pulmonary function and reduced virus titer and body weight loss in mice infected with SARS&#x02010; and MERS&#x02010;CoV. These promising results suggest that NHC molecules might be considered for Covid&#x02010;19 treatment,<xref rid="rmv2143-bib-0053" ref-type="ref">
<sup>53</sup>
</xref>, <xref rid="rmv2143-bib-0072" ref-type="ref">
<sup>72</sup>
</xref> and should be assessed in clinical trials. Another potential treatment is the guanine analog favipiravir (T&#x02010;705) that was initially developed for influenza virus,<xref rid="rmv2143-bib-0073" ref-type="ref">
<sup>73</sup>
</xref> but has a broad&#x02010;spectrum activity, with antiviral effects against flaviviruses,<xref rid="rmv2143-bib-0074" ref-type="ref">
<sup>74</sup>
</xref>, <xref rid="rmv2143-bib-0075" ref-type="ref">
<sup>75</sup>
</xref> alphaviruses,<xref rid="rmv2143-bib-0076" ref-type="ref">
<sup>76</sup>
</xref> noroviruses,<xref rid="rmv2143-bib-0077" ref-type="ref">
<sup>77</sup>
</xref> and Ebola virus.<xref rid="rmv2143-bib-0078" ref-type="ref">
<sup>78</sup>
</xref>, <xref rid="rmv2143-bib-0079" ref-type="ref">
<sup>79</sup>
</xref>, <xref rid="rmv2143-bib-0080" ref-type="ref">
<sup>80</sup>
</xref> Favipiravir was approved for influenza treatment in Japan in 2014, and is currently assessed for Covid&#x02010;19 treatment in several clinical trials.<xref rid="rmv2143-bib-0042" ref-type="ref">
<sup>42</sup>
</xref>, <xref rid="rmv2143-bib-0051" ref-type="ref">
<sup>51</sup>
</xref> The preliminary results suggest a faster viral clearance time in the favipiravir arm compared with the control arm.<xref rid="rmv2143-bib-0051" ref-type="ref">
<sup>51</sup>
</xref> More recently, in&#x02009;vitro studies demonstrate that favipiravir exerts an antiviral effect as a nucleotide analogue through a combination of chain termination, slowed RNA synthesis and lethal mutagenesis. The use of favipiravir in infected cells induces C&#x02010;to&#x02010;U and G&#x02010;to&#x02010;A changes.<xref rid="rmv2143-bib-0081" ref-type="ref">
<sup>81</sup>
</xref> A last nucleoside analog potentially active against SARS&#x02010;CoV&#x02010;2 is sofosbuvir, a broad&#x02010;acting antiviral approved for hepatitis C virus infection management. A recent study showed that sofosbuvir triphosphate is incorporated by recombinant SARS&#x02010;CoV&#x02010;2 RdRp during RNA elongation.<xref rid="rmv2143-bib-0054" ref-type="ref">
<sup>54</sup>
</xref> More work is needed to confirm its antiviral effect in infected cells and animal models before moving to clinical trials.</p></sec></sec><sec id="rmv2143-sec-0005"><label>3</label><title>DRUG REPOSITIONING STRATEGIES FOR COVID&#x02010;19 TREATMENT</title><p>The fastest option for the treatment of Covid&#x02010;19 is the identification of already approved drugs that were developed for other diseases, but that show inhibitory activity against SARS&#x02010;CoV&#x02010;2 in infected cells. The main advantages of this strategy are that these drugs are available on the market, and their safety and toxicity profiles are already documented. However, their MoA against the virus is often speculative, and the efficacy and clinical doses required for treatment in patients with Covid&#x02010;19 are unknown, due to the absence of large&#x02010;scale clinical studies. Moreover, it is important to consider the risk of overdose and of unexpected increase of viral load or symptoms. Several teams have already set up platforms to screen FDA&#x02010;approved libraries using SARS&#x02010;CoV&#x02010;2 infected cells.<xref rid="rmv2143-bib-0039" ref-type="ref">
<sup>39</sup>
</xref>, <xref rid="rmv2143-bib-0064" ref-type="ref">
<sup>64</sup>
</xref>, <xref rid="rmv2143-bib-0082" ref-type="ref">
<sup>82</sup>
</xref> Although the chemical libraries and experimental conditions used in these studies are quite different, a comparative analysis of their results reveals that some compounds, such as chloroquine derivatives, have been identified in different experimental conditions. Moreover, several groups reported the antiviral activity of FDA&#x02010;approved compounds, and some of them are already tested in clinical trials.<xref rid="rmv2143-bib-0015" ref-type="ref">
<sup>15</sup>
</xref> In this review, we cannot discuss all drugs identified by this strategy. Therefore, we selected the key compounds that are already in clinical trials and the most interesting classes of compounds, based on their potential MoA on CoV life cycle inferred from their known activity.</p><sec id="rmv2143-sec-0006"><label>3.1</label><title>Immunomodulators</title><p>As some patients with Covid&#x02010;19 show an inefficient antiviral response, it has been suggested that immunomodulators might restore the immune system homeostasis. For instance, interferon (IFN) could be used during the early stages of infection to boost the innate immune response and promote viral clearance. IFN treatments are being tested in several clinical trials, but results are not available yet. However, as SARS&#x02010;CoV&#x02010;2 infection may also be accompanied by a dysregulated immune response leading to a massive production of pro&#x02010;inflammatory cytokines, IFN treatment could have unexpected effects.<xref rid="rmv2143-bib-0005" ref-type="ref">
<sup>5</sup>
</xref>, <xref rid="rmv2143-bib-0083" ref-type="ref">
<sup>83</sup>
</xref>, <xref rid="rmv2143-bib-0084" ref-type="ref">
<sup>84</sup>
</xref>, <xref rid="rmv2143-bib-0085" ref-type="ref">
<sup>85</sup>
</xref>, <xref rid="rmv2143-bib-0086" ref-type="ref">
<sup>86</sup>
</xref> Indeed, IFN triggers overexpression of ACE2, even in cell lines with low basal expression level, leading to a larger dissemination of SARS&#x02010;CoV&#x02010;2.<xref rid="rmv2143-bib-0087" ref-type="ref">
<sup>87</sup>
</xref> Conversely, in the second phase of the disease, the use of molecules that limit the effect of the cytokine storm could be advantageous. For instance, the mAbs mepolizumab against interleukin (IL)&#x02010;5, tocilizumab against IL&#x02010;6 receptor,<xref rid="rmv2143-bib-0088" ref-type="ref">
<sup>88</sup>
</xref> as well as anakinra an interleukin 1 receptor antagonist<xref rid="rmv2143-bib-0089" ref-type="ref">
<sup>89</sup>
</xref> could control the immune response, and be of therapeutic interest for managing the production of pro&#x02010;inflammatory cytokines in patients with severe infection.<xref rid="rmv2143-bib-0090" ref-type="ref">
<sup>90</sup>
</xref> Finally, Dexamethasone, used to reduce inflammation, has been tested in RECOVERY clinical trial and shown first promising results. Indeed, treatment with Dexamethasone reduces death by one&#x02010;third to one&#x02010;fifth.<xref rid="rmv2143-bib-0091" ref-type="ref">
<sup>91</sup>
</xref>
</p></sec><sec id="rmv2143-sec-0007"><label>3.2</label><title>Repositioned drugs that interfere with the viral life cycle</title><p>Several therapeutic molecules (Table <xref rid="rmv2143-tbl-0002" ref-type="table">2</xref>), identified in antiviral screenings performed in infected cells, target the renin/angiotensin pathway.<xref rid="rmv2143-bib-0039" ref-type="ref">
<sup>39</sup>
</xref>, <xref rid="rmv2143-bib-0100" ref-type="ref">
<sup>100</sup>
</xref>, <xref rid="rmv2143-bib-0101" ref-type="ref">
<sup>101</sup>
</xref> The MoA of these class of inhibitors is speculative. Interestingly, ACE2 belongs to this pathway. An in&#x02009;vivo study has shown that inhibition of the renin/angiotensin pathway upregulates of ACE2 which can increase susceptibility to SARS&#x02010;CoV&#x02010;2 infection.<xref rid="rmv2143-bib-0102" ref-type="ref">
<sup>102</sup>
</xref> More recently, it has been shown that treatment target this pathway is not associated with higher severity of COVID19<xref rid="rmv2143-bib-0103" ref-type="ref">
<sup>103</sup>
</xref> Additional work is needed to understand how these compounds inhibit the virus before planning clinical trials.</p><table-wrap id="rmv2143-tbl-0002" xml:lang="en" content-type="TABLE" orientation="portrait" position="float"><label>TABLE 2</label><caption><p>Main repositioning molecules currently being tested against SARS&#x02010;CoV&#x02010;2 infection</p></caption><table frame="hsides" rules="groups"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><thead valign="bottom"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="bottom" rowspan="1" colspan="1">Compounds</th><th align="left" valign="bottom" rowspan="1" colspan="1">Target/MoA</th><th align="left" valign="bottom" rowspan="1" colspan="1">Tests in vitro (CoV)</th><th align="left" valign="bottom" rowspan="1" colspan="1">Clinical trials SARS&#x02010;CoV&#x02010;2</th></tr></thead><tbody valign="top"><tr><td colspan="4" align="left" valign="top" rowspan="1">
<italic>Antivirals</italic>
</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Nafamostat mesylate</td><td align="left" valign="top" rowspan="1" colspan="1">TMPRSS2/inhibitor</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="rmv2143-bib-0092" ref-type="ref">92</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">No data</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Camostat mesylate</td><td align="left" valign="top" rowspan="1" colspan="1">TMPRSS2/inhibitor</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="rmv2143-bib-0039" ref-type="ref">39</xref>, <xref rid="rmv2143-bib-0092" ref-type="ref">92</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">No data</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">
<p>Chloroquine</p>
<p>Hydroxychloroquine</p>
</td><td align="left" valign="top" rowspan="1" colspan="1">pH increases in endosomal compartment</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="rmv2143-bib-0039" ref-type="ref">39</xref>, <xref rid="rmv2143-bib-0048" ref-type="ref">48</xref>, <xref rid="rmv2143-bib-0093" ref-type="ref">93</xref>, <xref rid="rmv2143-bib-0094" ref-type="ref">94</xref>, <xref rid="rmv2143-bib-0095" ref-type="ref">95</xref>, <xref rid="rmv2143-bib-0096" ref-type="ref">96</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0201c;Solidarity,&#x0201d; &#x0201c;Discovery&#x0201d; NCT04358068 (<xref rid="rmv2143-bib-0049" ref-type="ref">49</xref>, <xref rid="rmv2143-bib-0097" ref-type="ref">97</xref>, <xref rid="rmv2143-bib-0098" ref-type="ref">98</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Azithromycin (antibiotic)</td><td align="left" valign="top" rowspan="1" colspan="1">pH increases in endosomal compartment/immunomodulator</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="rmv2143-bib-0039" ref-type="ref">39</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">NCT04358068 (<xref rid="rmv2143-bib-0098" ref-type="ref">98</xref>)</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Omeprazole</td><td align="left" valign="top" rowspan="1" colspan="1">PPI</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="rmv2143-bib-0039" ref-type="ref">39</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">No data</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Vonoprazan</td><td align="left" valign="top" rowspan="1" colspan="1">PPI</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="rmv2143-bib-0039" ref-type="ref">39</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">No data</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Ivermectin</td><td align="left" valign="top" rowspan="1" colspan="1">Limits viral infection</td><td align="left" valign="top" rowspan="1" colspan="1">(<xref rid="rmv2143-bib-0099" ref-type="ref">99</xref>)</td><td align="left" valign="top" rowspan="1" colspan="1">No data</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Oseltamivir</td><td align="left" valign="top" rowspan="1" colspan="1">Neuraminidase inhibitor</td><td align="left" valign="top" rowspan="1" colspan="1">No data</td><td align="left" valign="top" rowspan="1" colspan="1">No data</td></tr></tbody></table><table-wrap-foot id="rmv2143-ntgp-0002"><fn id="rmv2143-note-0002"><p>
<italic>Note:</italic> Clinical trials web site: <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/results?cond=SARS-CoV2%26term=%26cntry=%26state=%26city=%26dist=">https://clinicaltrials.gov/ct2/results?cond=SARS&#x02010;CoV2&#x00026;term=&#x00026;cntry=&#x00026;state=&#x00026;city=&#x00026;dist=</ext-link>.</p></fn><fn id="rmv2143-note-0003"><p>Abbreviations: CoV, coronaviruses; MoA, mode of action; PPI, proton pump inhibitor; TMPRSS2, transmembrane protease serine 2.</p></fn></table-wrap-foot></table-wrap><p>Once the virus binds to the target cell, the S protein is cleaved by cellular proteases into the S1 and S2 subunits (priming), and also upstream of the fusion peptide (S2&#x02019; cleavage site). The serine protease TMPRSS2, which is strongly expressed in lung cells, can cleave a variety of CoV S proteins,<xref rid="rmv2143-bib-0012" ref-type="ref">
<sup>12</sup>
</xref>, <xref rid="rmv2143-bib-0013" ref-type="ref">
<sup>13</sup>
</xref> and seems to play a key role in virus entry.<xref rid="rmv2143-bib-0014" ref-type="ref">
<sup>14</sup>
</xref> Camostat mesylate, a TMPRSS2 inhibitor approved for clinical use, blocks S protein processing in&#x02009;vitro.<xref rid="rmv2143-bib-0092" ref-type="ref">
<sup>92</sup>
</xref> Moreover, camostat mesylate and its derivative nafamostat mesylate can inhibit (in the nM to &#x003bc;M range) the entry of vesicular stomatitis virus pseudotypes carrying the SARS&#x02010;CoV&#x02010;2 S protein in different cell types that overexpress TMPRSS2.<xref rid="rmv2143-bib-0092" ref-type="ref">
<sup>92</sup>
</xref>, <xref rid="rmv2143-bib-0104" ref-type="ref">
<sup>104</sup>
</xref> This observation suggests that inhibition of S protein priming blocks ACE2&#x02010;mediated entry. However, the inhibition observed with camostat mesylate and nafamostat mesylate in VeroE6 cells infected by SARS&#x02010;CoV&#x02010;2 is lower and probably not enough for a therapeutic utilization of camostat mesylate. The picture is further complicated because other cellular proteases could be implicated in S protein processing. Indeed, cathepsin L<xref rid="rmv2143-bib-0105" ref-type="ref">
<sup>105</sup>
</xref> and furin<xref rid="rmv2143-bib-0009" ref-type="ref">
<sup>9</sup>
</xref> might be involved in S protein activation, depending on the infected cell type. Consequently, inhibitors of these different enzymes might limit virus propagation in some cell types, but their efficacy in the clinic could be limited. Perhaps, the best option is to combine furin and TMPRSS2 inhibitors to limit virus propagation.<xref rid="rmv2143-bib-0014" ref-type="ref">
<sup>14</sup>
</xref>
</p><p>Interestingly, several compounds identified in different screens of infected cells are implicated in endosomal acidification.<xref rid="rmv2143-bib-0039" ref-type="ref">
<sup>39</sup>
</xref>, <xref rid="rmv2143-bib-0100" ref-type="ref">
<sup>100</sup>
</xref>, <xref rid="rmv2143-bib-0101" ref-type="ref">
<sup>101</sup>
</xref> Increasing the endosomal pH might limit viral/endosomal membrane fusion, which is necessary for the release of the viral genome into the cytoplasm of the host cell. Two recent studies showed that proton pump inhibitors, such as omeprazole and vonoprazan, reduce the infection of cells by SARS&#x02010;CoV&#x02010;2.<xref rid="rmv2143-bib-0039" ref-type="ref">
<sup>39</sup>
</xref>, <xref rid="rmv2143-bib-0064" ref-type="ref">
<sup>64</sup>
</xref> In addition, chloroquine and hydroxychloroquine (HCQ), which have been extensively used for the treatment of malaria with known safety and efficacy, also limit acidification of endosomes, Golgi vesicles, and lysosomes.<xref rid="rmv2143-bib-0106" ref-type="ref">
<sup>106</sup>
</xref> These molecules significantly reduce SARS&#x02010;CoV and SARS&#x02010;CoV&#x02010;2 infection in&#x02009;vitro.<xref rid="rmv2143-bib-0048" ref-type="ref">
<sup>48</sup>
</xref>, <xref rid="rmv2143-bib-0093" ref-type="ref">
<sup>93</sup>
</xref>, <xref rid="rmv2143-bib-0094" ref-type="ref">
<sup>94</sup>
</xref>, <xref rid="rmv2143-bib-0095" ref-type="ref">
<sup>95</sup>
</xref>, <xref rid="rmv2143-bib-0106" ref-type="ref">
<sup>106</sup>
</xref>, <xref rid="rmv2143-bib-0107" ref-type="ref">
<sup>107</sup>
</xref> However, a recent study reported that HCQ does not have any effect on viral load levels and does not protect macaques against SARS&#x02010;CoV infection.<xref rid="rmv2143-bib-0108" ref-type="ref">
<sup>108</sup>
</xref> Moreover, chloroquine derivatives have immunosuppressive effects and inhibit the activation of innate immune receptors, such as toll&#x02010;like receptors<xref rid="rmv2143-bib-0109" ref-type="ref">
<sup>109</sup>
</xref> and have been associated with some adverse cardiac effects. Many clinical studies are currently testing these molecules,<xref rid="rmv2143-bib-0097" ref-type="ref">
<sup>97</sup>
</xref>, <xref rid="rmv2143-bib-0098" ref-type="ref">
<sup>98</sup>
</xref> and their initial results are controversial.<xref rid="rmv2143-bib-0110" ref-type="ref">
<sup>110</sup>
</xref> Randomized, double&#x02010;blind studies with a larger number of patients should bring robust conclusions. Recent in&#x02009;vitro studies have also suggested the therapeutic effect of the HCQ&#x02010;azithromycin combination.<xref rid="rmv2143-bib-0098" ref-type="ref">
<sup>98</sup>
</xref> Azithromycin is an antibiotic that has also antiviral activity in respiratory viral infections.<xref rid="rmv2143-bib-0111" ref-type="ref">
<sup>111</sup>
</xref> Interestingly, the MoA of azithromycin and HCQ may be related to the modulation of the endosomal and trans&#x02010;Golgi network pH.<xref rid="rmv2143-bib-0112" ref-type="ref">
<sup>112</sup>
</xref>, <xref rid="rmv2143-bib-0113" ref-type="ref">
<sup>113</sup>
</xref> In addition, azithromycin plays a role in regulating interleukin production that might help to control the immune response and prevent symptom worsening.<xref rid="rmv2143-bib-0114" ref-type="ref">
<sup>114</sup>
</xref>, <xref rid="rmv2143-bib-0115" ref-type="ref">
<sup>115</sup>
</xref>, <xref rid="rmv2143-bib-0116" ref-type="ref">
<sup>116</sup>
</xref> Azithromycin may also inhibit viral invasion by interfering with the CD147&#x02010;mediated recognition mechanism.<xref rid="rmv2143-bib-0117" ref-type="ref">
<sup>117</sup>
</xref> Nevertheless, both the FDA and the World Health Organization (WHO) have removed their support for the use of HCQ and chloroquine for COVID&#x02010;19, consequently the status of ongoing trials must be questioned.</p><p>More recently, it has been reported that ivermectin inhibits SARS&#x02010;CoV&#x02010;2 with an ~5000&#x02010;fold reduction in viral RNA after 48&#x02009;hours.<xref rid="rmv2143-bib-0099" ref-type="ref">
<sup>99</sup>
</xref> Ivermectin is a FDA&#x02010;approved antiparasitic molecule, initially identified as an inhibitor of HIV protein nuclear import.<xref rid="rmv2143-bib-0118" ref-type="ref">
<sup>118</sup>
</xref> Its broad&#x02010;spectrum antiviral activity was documented in&#x02009;vitro.<xref rid="rmv2143-bib-0119" ref-type="ref">
<sup>119</sup>
</xref>, <xref rid="rmv2143-bib-0120" ref-type="ref">
<sup>120</sup>
</xref> Ivermectin perturbs nuclear import through IMP&#x003b1;/&#x003b2;1; however, the role of this machinery during the CoV life cycle has not been elucidated yet. Nevertheless, an observational study reported survival benefits during hospitalization,<xref rid="rmv2143-bib-0121" ref-type="ref">
<sup>121</sup>
</xref> but no data on viral load, highlighting the necessity to validate this observation in clinical trials. Recent review presents the pharmacokinetic properties of ivermectin, and highlights that the dose currently used for parasitic disease do not effective against SARS infection.<xref rid="rmv2143-bib-0122" ref-type="ref">
<sup>122</sup>
</xref>
</p><p>Finally, oseltamivir, a neuraminidase inhibitor that prevents influenza viral particle release, is also investigated.<xref rid="rmv2143-bib-0123" ref-type="ref">
<sup>123</sup>
</xref> Like for ritonavir/lopinavir, there is no molecular basis to support these trials because to the best of our knowledge, CoVs (unlike influenza viruses) do not rely on neuraminidases during their life cycle. If antiviral effect are observed, the off&#x02010;target mechanisms will have to be elucidated.</p></sec></sec><sec sec-type="COI-statement" id="rmv2143-sec-0009"><title>CONFLICT OF INTEREST</title><p>The authors have no competing interest.</p></sec><sec id="rmv2143-sec-0010"><title>AUTHOR CONTRIBUTIONS</title><p>Coralie Valle, Baptiste Martin, Bruno Coutard, and Etienne Decroly were major contributors to writing the manuscript. Coralie Valle, Baptiste Martin, Franck Touret, Ashleigh Shannon, Bruno Canard, Jean Claude Guillemot, Bruno Coutard, and Etienne Decroly checked and revised the manuscript. All authors read and approved the final version.</p></sec></body><back><ack id="rmv2143-sec-0008"><title>ACKNOWLEDGMENTS</title><p>This work was partly supported by Inserm through the REACTing initiative (REsearch and ACTion targeting emerging infectious diseases), a multidisciplinary collaborative network of French research institutions working on emerging infectious diseases, which aims to prepare and respond to epidemics (B. Canard, B. Coutard, E. D.), and by the Fondation pour la Recherche M&#x000e9;dicale (Aide aux &#x000e9;quipes, B. Canard, E. D.). The SCORE project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 101003627.</p></ack><ref-list id="rmv2143-bibl-0001" content-type="cited-references"><title>REFERENCES</title><ref id="rmv2143-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="rmv2143-cit-0001">
<string-name>
<surname>Ksiazek</surname>
<given-names>TG</given-names>
</string-name>, <string-name>
<surname>Erdman</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Goldsmith</surname>
<given-names>CS</given-names>
</string-name>, et al. <article-title>A novel coronavirus associated with severe acute respiratory syndrome</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2003</year>;<volume>348</volume>(<issue>20</issue>):<fpage>1953</fpage>&#x02010;<lpage>1966</lpage>.<pub-id pub-id-type="pmid">12690092</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="rmv2143-cit-0002">
<string-name>
<surname>Zaki</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>van Boheemen</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Bestebroer</surname>
<given-names>TM</given-names>
</string-name>, <string-name>
<surname>Osterhaus</surname>
<given-names>ADME</given-names>
</string-name>, <string-name>
<surname>RAM</surname>
<given-names>F</given-names>
</string-name>. <article-title>Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2012</year>;<volume>367</volume>(<issue>19</issue>):<fpage>1814</fpage>&#x02010;<lpage>1820</lpage>.<pub-id pub-id-type="pmid">23075143</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="rmv2143-cit-0003">
<string-name>
<surname>Wu</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Zhao</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Yu</surname>
<given-names>B</given-names>
</string-name>, et al. <article-title>A new coronavirus associated with human respiratory disease in China</article-title>. <source xml:lang="en">Nature</source>. <year>2020</year>;<volume>579</volume>(<issue>7798</issue>):<fpage>265</fpage>&#x02010;<lpage>269</lpage>.<pub-id pub-id-type="pmid">32015508</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="rmv2143-cit-0004">
<string-name>
<surname>Zhou</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Yu</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Du</surname>
<given-names>R</given-names>
</string-name>, et al. <article-title>Clinical course and risk factors for mortality of adult inpatients with COVID&#x02010;19 in Wuhan, China: a retrospective cohort study</article-title>. <source xml:lang="en">Lancet</source>. <year>2020</year>;<volume>395</volume>(<issue>10229</issue>):<fpage>1054</fpage>&#x02010;<lpage>1062</lpage>.<pub-id pub-id-type="pmid">32171076</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="rmv2143-cit-0005">
<string-name>
<surname>Huang</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>X</given-names>
</string-name>, et al. <article-title>Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</article-title>. <source xml:lang="en">Lancet</source>. <year>2020</year>;<volume>395</volume>(<issue>10223</issue>):<fpage>497</fpage>&#x02010;<lpage>506</lpage>.<pub-id pub-id-type="pmid">31986264</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="rmv2143-cit-0006">
<string-name>
<surname>de Wit</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>van Doremalen</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Falzarano</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Munster</surname>
<given-names>VJ</given-names>
</string-name>. <article-title>SARS and MERS: recent insights into emerging coronaviruses</article-title>. <source xml:lang="en">Nat Rev Microbiol</source>. <year>2016</year>;<volume>14</volume>(<issue>8</issue>):<fpage>523</fpage>&#x02010;<lpage>534</lpage>.<pub-id pub-id-type="pmid">27344959</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="rmv2143-cit-0007">
<string-name>
<surname>Li</surname>
<given-names>F</given-names>
</string-name>. <article-title>Receptor recognition mechanisms of coronaviruses: a decade of structural studies</article-title>. <source xml:lang="en">J Virol</source>. <year>2015</year>;<volume>89</volume>(<issue>4</issue>):<fpage>1954</fpage>&#x02010;<lpage>1964</lpage>.<pub-id pub-id-type="pmid">25428871</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="rmv2143-cit-0008">
<string-name>
<surname>Wan</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Shang</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Graham</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Baric</surname>
<given-names>RS</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>F</given-names>
</string-name>. <article-title>Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade&#x02010;long structural studies of SARS coronavirus</article-title>. <source xml:lang="en">J Virol</source>. <year>2020</year>;<volume>94</volume>(<issue>7</issue>):<fpage>120</fpage>&#x02013;<lpage>127</lpage>. </mixed-citation></ref><ref id="rmv2143-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="rmv2143-cit-0009">
<string-name>
<surname>Coutard</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Valle</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>de Lamballerie</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Canard</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Seidah</surname>
<given-names>NG</given-names>
</string-name>, <string-name>
<surname>Decroly</surname>
<given-names>E</given-names>
</string-name>. <article-title>The spike glycoprotein of the new coronavirus 2019&#x02010;nCoV contains a furin&#x02010;like cleavage site absent in CoV of the same clade</article-title>. <source xml:lang="en">Antiviral Res</source>. <year>2020</year>;<volume>176</volume>:<elocation-id>104742</elocation-id>.<pub-id pub-id-type="pmid">32057769</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="rmv2143-cit-0010">
<string-name>
<surname>Matsuyama</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Nagata</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Shirato</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Kawase</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Takeda</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Taguchi</surname>
<given-names>F</given-names>
</string-name>. <article-title>Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2</article-title>. <source xml:lang="en">J Virol</source>. <year>2010</year>;<volume>84</volume>(<issue>24</issue>):<fpage>12658</fpage>&#x02010;<lpage>12664</lpage>.<pub-id pub-id-type="pmid">20926566</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="rmv2143-cit-0011">
<string-name>
<surname>Markus</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Kleine&#x02010;Weber</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>P&#x000f6;hlmann</surname>
<given-names>S</given-names>
</string-name>. <article-title>A multibasic cleavage site in the spike protein of SARS&#x02010;CoV&#x02010;2 is essential for infection of human lung cells</article-title>. <source xml:lang="en">Mol Cell</source>. <year>2020</year>;<volume>78</volume>(<issue>4</issue>):<fpage>779</fpage>&#x02013;<lpage>784</lpage>. <pub-id pub-id-type="pmid">32362314</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="rmv2143-cit-0012">
<string-name>
<surname>Belouzard</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Chu</surname>
<given-names>VC</given-names>
</string-name>, <string-name>
<surname>Whittaker</surname>
<given-names>GR</given-names>
</string-name>. <article-title>Activation of the SARS coronavirus spike protein via sequential proteolytic cleavage at two distinct sites</article-title>. <source xml:lang="en">Proc Natl Acad Sci U S A</source>. <year>2009</year>;<volume>106</volume>(<issue>14</issue>):<fpage>5871</fpage>&#x02010;<lpage>5876</lpage>.<pub-id pub-id-type="pmid">19321428</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="rmv2143-cit-0013">
<string-name>
<surname>Millet</surname>
<given-names>JK</given-names>
</string-name>, <string-name>
<surname>Whittaker</surname>
<given-names>GR</given-names>
</string-name>. <article-title>Host cell proteases: critical determinants of coronavirus tropism and pathogenesis</article-title>. <source xml:lang="en">Virus Res</source>. <year>2015</year>;<volume>202</volume>:<fpage>120</fpage>&#x02010;<lpage>134</lpage>.<pub-id pub-id-type="pmid">25445340</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0014"><label>14</label><mixed-citation publication-type="miscellaneous" id="rmv2143-cit-0014">
<string-name>
<surname>Bestle</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Heindl</surname>
<given-names>MR</given-names>
</string-name>, <string-name>
<surname>Limburg</surname>
<given-names>H</given-names>
</string-name>, et al. TMPRSS2 and furin are both essential for proteolytic activation and spread of SARS&#x02010;CoV&#x02010;2 in human airway epithelial cells and provide promising drug targets. bioRxiv;2020.04.15.042085. <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2020.04.15.042085v1.abstract">https://www.biorxiv.org/content/10.1101/2020.04.15.042085v1.abstract</ext-link>. [Accessed May 1, 2020].</mixed-citation></ref><ref id="rmv2143-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="rmv2143-cit-0015">
<string-name>
<surname>Thorlund</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Dron</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Park</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Hsu</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Forrest</surname>
<given-names>JI</given-names>
</string-name>, <string-name>
<surname>Mills</surname>
<given-names>EJ</given-names>
</string-name>. <article-title>A real&#x02010;time dashboard of clinical trials for COVID&#x02010;19</article-title>. <source xml:lang="en">Lancet Digit Heal</source>. <year>2020</year>;<volume>2</volume>:<fpage>286</fpage>&#x02013;<lpage>287</lpage>. </mixed-citation></ref><ref id="rmv2143-bib-0016"><label>16</label><mixed-citation publication-type="miscellaneous" id="rmv2143-cit-0016">Clinical Management of Severe Acute Respiratory Infection When COVID&#x02010;19 Is Suspected. <ext-link ext-link-type="uri" xlink:href="https://www.who.int/publications/i/item/clinical-management-of-covid-19">https://www.who.int/publications/i/item/clinical-management-of-covid-19</ext-link>. Accessed May 27, 2020.</mixed-citation></ref><ref id="rmv2143-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="rmv2143-cit-0017">
<string-name>
<surname>Zhou</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Zhao</surname>
<given-names>Q</given-names>
</string-name>. <article-title>Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS&#x02010;CoV&#x02010;2</article-title>. <source xml:lang="en">Int J Biol Sci</source>. <year>2020</year>;<volume>16</volume>(<issue>10</issue>):<fpage>1718</fpage>&#x02010;<lpage>1723</lpage>.<pub-id pub-id-type="pmid">32226289</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="rmv2143-cit-0018">
<string-name>
<surname>Cheng</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Wong</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Soo</surname>
<given-names>YOY</given-names>
</string-name>, et al. <article-title>Use of convalescent plasma therapy in SARS patients in Hong Kong</article-title>. <source xml:lang="en">Eur J Clin Microbiol Infect Dis</source>. <year>2005</year>;<volume>24</volume>(<issue>1</issue>):<fpage>44</fpage>&#x02010;<lpage>46</lpage>.<pub-id pub-id-type="pmid">15616839</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="rmv2143-cit-0019">
<string-name>
<surname>Mair&#x02010;Jenkins</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Saavedra&#x02010;Campos</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Baillie</surname>
<given-names>JK</given-names>
</string-name>, et al. <article-title>The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta&#x02010;analysis</article-title>. <source xml:lang="en">J Infect Dis</source>. <year>2015</year>;<volume>211</volume>(<issue>1</issue>):<fpage>80</fpage>&#x02010;<lpage>90</lpage>.<pub-id pub-id-type="pmid">25030060</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="rmv2143-cit-0020">
<string-name>
<surname>Yeh</surname>
<given-names>K&#x02010;M</given-names>
</string-name>, <string-name>
<surname>Chiueh</surname>
<given-names>T&#x02010;S</given-names>
</string-name>, <string-name>
<surname>Siu</surname>
<given-names>LK</given-names>
</string-name>, et al. <article-title>Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital</article-title>. <source xml:lang="en">J Antimicrob Chemother</source>. <year>2005</year>;<volume>56</volume>(<issue>5</issue>):<fpage>919</fpage>&#x02010;<lpage>922</lpage>.<pub-id pub-id-type="pmid">16183666</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="rmv2143-cit-0021">
<string-name>
<surname>Chen</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Xiong</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Bao</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Shi</surname>
<given-names>Y</given-names>
</string-name>. <article-title>Convalescent plasma as a potential therapy for COVID&#x02010;19</article-title>. <source xml:lang="en">Lancet Infect Dis</source>. <year>2020</year>;<volume>20</volume>(<issue>4</issue>):<fpage>398</fpage>&#x02010;<lpage>400</lpage>.<pub-id pub-id-type="pmid">32113510</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="rmv2143-cit-0022">
<string-name>
<surname>Shen</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Zhao</surname>
<given-names>F</given-names>
</string-name>, et al. <article-title>Treatment of 5 critically ill patients with COVID&#x02010;19 with convalescent plasma</article-title>. <source xml:lang="en">JAMA</source>. <year>2020</year>;<volume>323</volume>:<fpage>1582</fpage>&#x02013;<lpage>1589</lpage>. </mixed-citation></ref><ref id="rmv2143-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="rmv2143-cit-0023">
<string-name>
<surname>Li</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Hu</surname>
<given-names>Y</given-names>
</string-name>, et al. <article-title>Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life&#x02010;threatening COVID&#x02010;19</article-title>. <source xml:lang="en">JAMA</source>. <year>2020</year>.</mixed-citation></ref><ref id="rmv2143-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="rmv2143-cit-0024">
<string-name>
<surname>Berry</surname>
<given-names>JD</given-names>
</string-name>. <article-title>Rational monoclonal antibody development to emerging pathogens, biothreat agents and agents of foreign animal disease: the antigen scale</article-title>. <source xml:lang="en">Vet J</source>. <year>2005</year>;<volume>170</volume>(<issue>2</issue>):<fpage>193</fpage>&#x02010;<lpage>211</lpage>.<pub-id pub-id-type="pmid">16129340</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="rmv2143-cit-0025">
<string-name>
<surname>Hoenen</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Groseth</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Feldmann</surname>
<given-names>H</given-names>
</string-name>. <article-title>Therapeutic strategies to target the Ebola virus life cycle</article-title>. <source xml:lang="en">Nat Rev Microbiol</source>. <year>2019</year>;<volume>17</volume>(<issue>10</issue>):<fpage>593</fpage>&#x02010;<lpage>606</lpage>.<pub-id pub-id-type="pmid">31341272</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="rmv2143-cit-0026">
<string-name>
<surname>Wang</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Shi</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Chappell</surname>
<given-names>JD</given-names>
</string-name>, et al. <article-title>Importance of neutralizing monoclonal antibodies targeting multiple antigenic sites on the Middle East respiratory syndrome coronavirus spike glycoprotein to avoid neutralization escape</article-title>. <source xml:lang="en">J Virol</source>. <year>2018</year>;<volume>92</volume>(<issue>10</issue>):<fpage>2002</fpage>&#x02013;<lpage>2017</lpage>. </mixed-citation></ref><ref id="rmv2143-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="rmv2143-cit-0027">
<string-name>
<surname>Hofmann</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Hattermann</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Marzi</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>S protein of severe acute respiratory syndrome&#x02010;associated coronavirus mediates entry into hepatoma cell lines and is targeted by neutralizing antibodies in infected patients</article-title>. <source xml:lang="en">J Virol</source>. <year>2004</year>;<volume>78</volume>(<issue>12</issue>):<fpage>6134</fpage>&#x02010;<lpage>6142</lpage>.<pub-id pub-id-type="pmid">15163706</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="rmv2143-cit-0028">
<string-name>
<surname>He</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Lu</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Siddiqui</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Zhou</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Jiang</surname>
<given-names>S</given-names>
</string-name>. <article-title>Receptor&#x02010;binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation&#x02010;dependent epitopes that induce highly potent neutralizing antibodies</article-title>. <source xml:lang="en">J Immunol</source>. <year>2005</year>;<volume>174</volume>(<issue>8</issue>):<fpage>4908</fpage>&#x02010;<lpage>4915</lpage>.<pub-id pub-id-type="pmid">15814718</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="rmv2143-cit-0029">
<string-name>
<surname>Sui</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Murakami</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association</article-title>. <source xml:lang="en">Proc Natl Acad Sci U S A</source>. <year>2004</year>;<volume>101</volume>(<issue>8</issue>):<fpage>2536</fpage>&#x02010;<lpage>2541</lpage>.<pub-id pub-id-type="pmid">14983044</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="rmv2143-cit-0030">
<string-name>
<surname>Greenough</surname>
<given-names>TC</given-names>
</string-name>, <string-name>
<surname>Babcock</surname>
<given-names>GJ</given-names>
</string-name>, <string-name>
<surname>Roberts</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Development and characterization of a severe acute respiratory syndrome&#x02013;associated coronavirus&#x02013;neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice</article-title>. <source xml:lang="en">J Infect Dis</source>. <year>2005</year>;<volume>191</volume>(<issue>4</issue>):<fpage>507</fpage>&#x02010;<lpage>514</lpage>.<pub-id pub-id-type="pmid">15655773</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="rmv2143-cit-0031">
<string-name>
<surname>Wrapp</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>De Vlieger</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Corbett</surname>
<given-names>KS</given-names>
</string-name>, et al. <article-title>Structural basis for potent neutralization of betacoronaviruses by single&#x02010;domain camelid antibodies</article-title>. <source xml:lang="en">Cell</source>. <year>2020</year>;<volume>181</volume>(<issue>5</issue>):<fpage>1004</fpage>&#x02013;<lpage>1015</lpage>. <pub-id pub-id-type="pmid">32375025</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="rmv2143-cit-0032">
<string-name>
<surname>Zhu</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Chakraborti</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>He</surname>
<given-names>Y</given-names>
</string-name>, et al. <article-title>Potent cross&#x02010;reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies</article-title>. <source xml:lang="en">Proc Natl Acad Sci U S A</source>. <year>2007</year>;<volume>104</volume>(<issue>29</issue>):<fpage>12123</fpage>&#x02010;<lpage>12128</lpage>.<pub-id pub-id-type="pmid">17620608</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="rmv2143-cit-0033">
<string-name>
<surname>Walls</surname>
<given-names>AC</given-names>
</string-name>, <string-name>
<surname>Park</surname>
<given-names>Y&#x02010;J</given-names>
</string-name>, <string-name>
<surname>Tortorici</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Wall</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>AT</surname>
<given-names>MG</given-names>
</string-name>, <string-name>
<surname>Veesler</surname>
<given-names>D</given-names>
</string-name>. <article-title>Structure, function, and antigenicity of the SARS&#x02010;CoV&#x02010;2 spike glycoprotein</article-title>. <source xml:lang="en">Cell</source>. <year>2020</year>;<volume>181</volume>:<fpage>281</fpage>&#x02013;<lpage>292</lpage>. <pub-id pub-id-type="pmid">32155444</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="rmv2143-cit-0034">
<string-name>
<surname>Monteil</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Kwon</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Prado</surname>
<given-names>P</given-names>
</string-name>, et al. <article-title>Inhibition of SARS&#x02010;CoV&#x02010;2 infections in engineered human tissues using clinical&#x02010;grade soluble human ACE2</article-title>. <source xml:lang="en">Cell</source>. <year>2020</year>;<volume>181</volume>:<fpage>905</fpage>&#x02013;<lpage>913</lpage>. <pub-id pub-id-type="pmid">32333836</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="rmv2143-cit-0035">
<string-name>
<surname>Imai</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Kuba</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Penninger</surname>
<given-names>JM</given-names>
</string-name>. <article-title>The discovery of angiotensin&#x02010;converting enzyme 2 and its role in acute lung injury in mice</article-title>. <source xml:lang="en">Exp Physiol</source>. <year>2008</year>;<volume>93</volume>:<fpage>543</fpage>&#x02010;<lpage>548</lpage>.<pub-id pub-id-type="pmid">18448662</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0036"><label>36</label><mixed-citation publication-type="miscellaneous" id="rmv2143-cit-0036">
<string-name>
<surname>Wang</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Zhou</surname>
<given-names>YS</given-names>
</string-name>, et al. SARS&#x02010;CoV&#x02010;2 invades host cells via a novel route: CD147&#x02010;spike protein. bioRxiv. <year>2020</year>
<ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2020.03.14.988345v1">https://www.biorxiv.org/content/10.1101/2020.03.14.988345v1</ext-link>. Accessed April 5, 2020.</mixed-citation></ref><ref id="rmv2143-bib-0037"><label>37</label><mixed-citation publication-type="miscellaneous" id="rmv2143-cit-0037">
<string-name>
<surname>Bian</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Zheng</surname>
<given-names>Z&#x02010;H</given-names>
</string-name>, <string-name>
<surname>Wei</surname>
<given-names>D</given-names>
</string-name>, et al. Meplazumab treats COVID&#x02010;19 pneumonia: an open&#x02010;labelled, concurrent controlled add&#x02010;on clinical trial. medRxiv. <year>2020</year>
<ext-link ext-link-type="uri" xlink:href="https://www.medrxiv.org/content/10.1101/2020.03.21.20040691v1">https://www.medrxiv.org/content/10.1101/2020.03.21.20040691v1</ext-link>. Accessed April 4, 2020.</mixed-citation></ref><ref id="rmv2143-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="rmv2143-cit-0038">
<string-name>
<surname>Boriskin</surname>
<given-names>YS</given-names>
</string-name>, <string-name>
<surname>Leneva</surname>
<given-names>IA</given-names>
</string-name>, <string-name>
<surname>P&#x000e9;cheur</surname>
<given-names>E&#x02010;I</given-names>
</string-name>, <string-name>
<surname>Polyak</surname>
<given-names>SJ</given-names>
</string-name>. <article-title>Arbidol: a broad&#x02010;spectrum antiviral compound that blocks viral fusion</article-title>. <source xml:lang="en">Curr Med Chem</source>. <year>2008</year>;<volume>15</volume>(<issue>10</issue>):<fpage>997</fpage>&#x02010;<lpage>1005</lpage>.<pub-id pub-id-type="pmid">18393857</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0039"><label>39</label><mixed-citation publication-type="miscellaneous" id="rmv2143-cit-0039">
<string-name>
<surname>Touret</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Gilles</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Barral</surname>
<given-names>K</given-names>
</string-name>, et al. in vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS&#x02010;CoV&#x02010;2 replication. bioRxiv. <year>2020</year>.</mixed-citation></ref><ref id="rmv2143-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="rmv2143-cit-0040">
<string-name>
<surname>Khamitov</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Loginova</surname>
<given-names>SI</given-names>
</string-name>, <string-name>
<surname>Shchukina</surname>
<given-names>VN</given-names>
</string-name>, <string-name>
<surname>Borisevich</surname>
<given-names>SV</given-names>
</string-name>, <string-name>
<surname>Maksimov</surname>
<given-names>VA</given-names>
</string-name>, <string-name>
<surname>Shuster</surname>
<given-names>AM</given-names>
</string-name>. <article-title>Antiviral activity of arbidol and its derivatives against the pathogen of severe acute respiratory syndrome in the cell cultures</article-title>. <source xml:lang="en">Vopr Virusol</source>. <year>2008</year>;<volume>53</volume>(<issue>4</issue>):<fpage>9</fpage>&#x02010;<lpage>13</lpage>.</mixed-citation></ref><ref id="rmv2143-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="rmv2143-cit-0041">
<string-name>
<surname>Deng</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Zeng</surname>
<given-names>Q</given-names>
</string-name>, et al. <article-title>Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: a retrospective cohort study</article-title>. <source xml:lang="en">J Infect</source>. <year>2020</year>;<volume>81</volume>:<fpage>1</fpage>&#x02013;<lpage>5</lpage>. <pub-id pub-id-type="pmid">32315723</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0042"><label>42</label><mixed-citation publication-type="miscellaneous" id="rmv2143-cit-0042">
<string-name>
<surname>Chen</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Huang</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Cheng</surname>
<given-names>Z</given-names>
</string-name>, et al. Favipiravir versus arbidol for COVID&#x02010;19: a randomized clinical trial. medRxiv. 2020. <ext-link ext-link-type="uri" xlink:href="https://www.medrxiv.org/content/10.1101/2020.03.17.20037432v2">https://www.medrxiv.org/content/10.1101/2020.03.17.20037432v2</ext-link>. Accessed April 4, 2020.</mixed-citation></ref><ref id="rmv2143-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="rmv2143-cit-0043">
<string-name>
<surname>Falzarano</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>de Wit</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Martellaro</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Callison</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Munster</surname>
<given-names>VJ</given-names>
</string-name>, <string-name>
<surname>Feldmann</surname>
<given-names>H</given-names>
</string-name>. <article-title>Inhibition of novel &#x003b2; coronavirus replication by a combination of interferon&#x02010;&#x003b1;2b and ribavirin</article-title>. <source xml:lang="en">Sci Rep</source>. <year>2013</year>;<volume>3</volume>(<issue>1</issue>):<fpage>1686</fpage>.<pub-id pub-id-type="pmid">23594967</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="rmv2143-cit-0044">
<string-name>
<surname>Barnard</surname>
<given-names>DL</given-names>
</string-name>, <string-name>
<surname>Day</surname>
<given-names>CW</given-names>
</string-name>, <string-name>
<surname>Bailey</surname>
<given-names>K</given-names>
</string-name>, et al. <article-title>Enhancement of the infectivity of SARS&#x02010;CoV in BALB/c mice by IMP dehydrogenase inhibitors, including ribavirin</article-title>. <source xml:lang="en">Antiviral Res</source>. <year>2006</year>;<volume>71</volume>(<issue>1</issue>):<fpage>53</fpage>&#x02010;<lpage>63</lpage>.<pub-id pub-id-type="pmid">16621037</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="rmv2143-cit-0045">
<string-name>
<surname>Warren</surname>
<given-names>TK</given-names>
</string-name>, <string-name>
<surname>Jordan</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Lo</surname>
<given-names>MK</given-names>
</string-name>, et al. <article-title>Therapeutic efficacy of the small molecule GS&#x02010;5734 against Ebola virus in rhesus monkeys</article-title>. <source xml:lang="en">Nature</source>. <year>2016</year>;<volume>531</volume>(<issue>7594</issue>):<fpage>381</fpage>&#x02010;<lpage>385</lpage>.<pub-id pub-id-type="pmid">26934220</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="rmv2143-cit-0046">
<string-name>
<surname>Agostini</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>Andres</surname>
<given-names>EL</given-names>
</string-name>, <string-name>
<surname>Sims</surname>
<given-names>AC</given-names>
</string-name>, et al. <article-title>Coronavirus susceptibility to the antiviral remdesivir (GS&#x02010;5734) is mediated by the viral polymerase and the proofreading exoribonuclease</article-title>. <source xml:lang="en">MBio</source>. <year>2018</year>;<volume>9</volume>(<issue>2</issue>):<fpage>e00221</fpage>&#x02013;<lpage>18</lpage>. <pub-id pub-id-type="pmid">29511076</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0047"><label>47</label><mixed-citation publication-type="journal" id="rmv2143-cit-0047">
<string-name>
<surname>de Wit</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Feldmann</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Cronin</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Prophylactic and therapeutic remdesivir (GS&#x02010;5734) treatment in the rhesus macaque model of MERS&#x02010;CoV infection</article-title>. <source xml:lang="en">Proc Natl Acad Sci U S A</source>. <year>2020</year>;<volume>117</volume>(<issue>12</issue>):<fpage>6771</fpage>&#x02010;<lpage>6776</lpage>.<pub-id pub-id-type="pmid">32054787</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0048"><label>48</label><mixed-citation publication-type="journal" id="rmv2143-cit-0048">
<string-name>
<surname>Wang</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Cao</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>L</given-names>
</string-name>, et al. <article-title>Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019&#x02010;nCoV) in vitro</article-title>. <source xml:lang="en">Cell Res</source>. <year>2020</year>;<volume>30</volume>(<issue>3</issue>):<fpage>269</fpage>&#x02010;<lpage>271</lpage>.<pub-id pub-id-type="pmid">32020029</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0049"><label>49</label><mixed-citation publication-type="miscellaneous" id="rmv2143-cit-0049">Launch of a European Clinical Trial Against COVID&#x02010;19 | Newsroom | INSERM. <ext-link ext-link-type="uri" xlink:href="https://presse.inserm.fr/en/launch-of-a-european-clinical-trial-against-covid-19/38737/">https://presse.inserm.fr/en/launch-of-a-european-clinical-trial-against-covid-19/38737/</ext-link>. Accessed April 6, 2020.</mixed-citation></ref><ref id="rmv2143-bib-0050"><label>50</label><mixed-citation publication-type="journal" id="rmv2143-cit-0050">
<string-name>
<surname>Grein</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Ohmagari</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Shin</surname>
<given-names>D</given-names>
</string-name>, et al. <article-title>Compassionate use of remdesivir for patients with severe Covid&#x02010;19</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2020</year>;<volume>382</volume>:<fpage>2327</fpage>&#x02013;<lpage>2336</lpage>. <pub-id pub-id-type="pmid">32275812</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0051"><label>51</label><mixed-citation publication-type="journal" id="rmv2143-cit-0051">
<string-name>
<surname>Cai</surname>
<given-names>Q</given-names>
</string-name>, <string-name>
<surname>Yang</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>D</given-names>
</string-name>, et al. <article-title>Experimental treatment with favipiravir for COVID&#x02010;19: an open&#x02010;label control study</article-title>. <source xml:lang="en">Engineering</source>, in press. <year>2020</year>.</mixed-citation></ref><ref id="rmv2143-bib-0052"><label>52</label><mixed-citation publication-type="journal" id="rmv2143-cit-0052">
<string-name>
<surname>Sheahan</surname>
<given-names>TP</given-names>
</string-name>, <string-name>
<surname>Sims</surname>
<given-names>AC</given-names>
</string-name>, <string-name>
<surname>Zhou</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>An orally bioavailable broad&#x02010;spectrum antiviral inhibits SARS&#x02010;CoV&#x02010;2 in human airway epithelial cell cultures and multiple coronaviruses in mice</article-title>. <source xml:lang="en">Sci Transl Med</source>. <year>2020</year>;<volume>12</volume>:<elocation-id>eabb5883</elocation-id>.<pub-id pub-id-type="pmid">32253226</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0053"><label>53</label><mixed-citation publication-type="journal" id="rmv2143-cit-0053">
<string-name>
<surname>Agostini</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>Pruijssers</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Chappell</surname>
<given-names>JD</given-names>
</string-name>, et al. <article-title>Small&#x02010;molecule antiviral &#x003b2;&#x02010;D&#x02010; N 4 &#x02010;hydroxycytidine inhibits a proofreading&#x02010;intact coronavirus with a high genetic barrier to resistance</article-title>. <source xml:lang="en">J Virol</source>. <year>2019</year>;<volume>93</volume>(<issue>24</issue>):<fpage>e01348</fpage>&#x02013;<lpage>19</lpage>.<pub-id pub-id-type="pmid">31578288</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0054"><label>54</label><mixed-citation publication-type="journal" id="rmv2143-cit-0054">
<string-name>
<surname>Gordon</surname>
<given-names>CJ</given-names>
</string-name>, <string-name>
<surname>Tchesnokov</surname>
<given-names>EP</given-names>
</string-name>, <string-name>
<surname>Woolner</surname>
<given-names>E</given-names>
</string-name>, et al. <article-title>Remdesivir is a direct&#x02010;acting antiviral that inhibits RNA&#x02010;dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency</article-title>. <source xml:lang="en">J Biol Chem</source>. <year>2020</year>;<volume>295</volume>:<fpage>6785</fpage>&#x02013;<lpage>6797</lpage>. <pub-id pub-id-type="pmid">32284326</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0055"><label>55</label><mixed-citation publication-type="journal" id="rmv2143-cit-0055">
<string-name>
<surname>Zhang</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Lin</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Sun</surname>
<given-names>X</given-names>
</string-name>, et al. <article-title>Crystal structure of SARS&#x02010;CoV&#x02010;2 main protease provides a basis for design of improved &#x003b1;&#x02010;ketoamide inhibitors</article-title>. <source xml:lang="en">Science</source>. <year>2020</year>;<volume>368</volume>:<fpage>409</fpage>&#x02013;<lpage>412</lpage>. <pub-id pub-id-type="pmid">32198291</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0056"><label>56</label><mixed-citation publication-type="journal" id="rmv2143-cit-0056">
<string-name>
<surname>Chu</surname>
<given-names>CM</given-names>
</string-name>, <string-name>
<surname>Cheng</surname>
<given-names>VCC</given-names>
</string-name>, <string-name>
<surname>Hung</surname>
<given-names>IFN</given-names>
</string-name>, et al. <article-title>Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings</article-title>. <source xml:lang="en">Thorax</source>. <year>2004</year>;<volume>59</volume>(<issue>3</issue>):<fpage>252</fpage>&#x02010;<lpage>256</lpage>.<pub-id pub-id-type="pmid">14985565</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0057"><label>57</label><mixed-citation publication-type="journal" id="rmv2143-cit-0057">
<string-name>
<surname>Bhatnagar</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Murhekar</surname>
<given-names>MV</given-names>
</string-name>, <string-name>
<surname>Soneja</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Lopinavir/ritonavir combination therapy amongst symptomatic coronavirus disease 2019 patients in India: protocol for restricted public health emergency use</article-title>. <source xml:lang="en">Indian J Med Res</source>. <year>2020</year>;<volume>151</volume>:<fpage>184</fpage>&#x02013;<lpage>189</lpage>. <pub-id pub-id-type="pmid">32362644</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0058"><label>58</label><mixed-citation publication-type="journal" id="rmv2143-cit-0058">
<string-name>
<surname>Cao</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Wen</surname>
<given-names>D</given-names>
</string-name>, et al. <article-title>A trial of lopinavir&#x02010;ritonavir in adults hospitalized with severe Covid&#x02010;19</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2020</year>;<volume>382</volume>:<fpage>1787</fpage>&#x02013;<lpage>1799</lpage>. <pub-id pub-id-type="pmid">32187464</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0059"><label>59</label><mixed-citation publication-type="journal" id="rmv2143-cit-0059">
<string-name>
<surname>Lim</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Jeon</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Shin</surname>
<given-names>HY</given-names>
</string-name>, et al. <article-title>Case of the index patient who caused tertiary transmission of COVID&#x02010;19 infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID&#x02010;19 infected pneumonia monitored by quantitative RT&#x02010;PCR</article-title>. <source xml:lang="en">J Korean Med Sci</source>. <year>2020</year>;<volume>35</volume>(<issue>6</issue>):<elocation-id>e79</elocation-id>.<pub-id pub-id-type="pmid">32056407</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0060"><label>60</label><mixed-citation publication-type="journal" id="rmv2143-cit-0060">
<string-name>
<surname>de Wilde</surname>
<given-names>AH</given-names>
</string-name>, <string-name>
<surname>Jochmans</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Posthuma</surname>
<given-names>CC</given-names>
</string-name>, et al. <article-title>Screening of an FDA&#x02010;approved compound library identifies four small&#x02010;molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture</article-title>. <source xml:lang="en">Antimicrob Agents Chemother</source>. <year>2014</year>;<volume>58</volume>(<issue>8</issue>):<fpage>4875</fpage>&#x02010;<lpage>4884</lpage>.<pub-id pub-id-type="pmid">24841269</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0061"><label>61</label><mixed-citation publication-type="journal" id="rmv2143-cit-0061">
<string-name>
<surname>Yamamoto</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Yang</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Yoshinaka</surname>
<given-names>Y</given-names>
</string-name>, et al. <article-title>HIV protease inhibitor nelfinavir inhibits replication of SARS&#x02010;associated coronavirus</article-title>. <source xml:lang="en">Biochem Biophys Res Commun</source>. <year>2004</year>;<volume>318</volume>(<issue>3</issue>):<fpage>719</fpage>&#x02010;<lpage>725</lpage>.<pub-id pub-id-type="pmid">15144898</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0062"><label>62</label><mixed-citation publication-type="journal" id="rmv2143-cit-0062">
<string-name>
<surname>Kadam</surname>
<given-names>RU</given-names>
</string-name>, <string-name>
<surname>Wilson</surname>
<given-names>IA</given-names>
</string-name>. <article-title>Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol</article-title>. <source xml:lang="en">Proc Natl Acad Sci U S A</source>. <year>2017</year>;<volume>114</volume>(<issue>2</issue>):<fpage>206</fpage>&#x02010;<lpage>214</lpage>.<pub-id pub-id-type="pmid">28003465</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0063"><label>63</label><mixed-citation publication-type="journal" id="rmv2143-cit-0063">
<string-name>
<surname>Vigant</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Santos</surname>
<given-names>NC</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>B</given-names>
</string-name>. <article-title>Broad&#x02010;spectrum antivirals against viral fusion</article-title>. <source xml:lang="en">Nat Rev Microbiol</source>. <year>2015</year>;<volume>13</volume>(<issue>7</issue>):<fpage>426</fpage>&#x02010;<lpage>437</lpage>.<pub-id pub-id-type="pmid">26075364</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0064"><label>64</label><mixed-citation publication-type="miscellaneous" id="rmv2143-cit-0064">
<string-name>
<surname>Riva</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Yuan</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Yin</surname>
<given-names>X</given-names>
</string-name>, et al. A large&#x02010;scale drug repositioning survey for SARS&#x02010;CoV&#x02010;2 antivirals. bioRxiv. 2020. <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2020.04.16.044016v1">https://www.biorxiv.org/content/10.1101/2020.04.16.044016v1</ext-link>. Accessed April 27, 2020.</mixed-citation></ref><ref id="rmv2143-bib-0065"><label>65</label><mixed-citation publication-type="journal" id="rmv2143-cit-0065">
<string-name>
<surname>Crotty</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Maag</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Arnold</surname>
<given-names>JJ</given-names>
</string-name>, et al. <article-title>The broad&#x02010;spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen</article-title>. <source xml:lang="en">Nat Med</source>. <year>2000</year>;<volume>6</volume>(<issue>12</issue>):<fpage>1375</fpage>&#x02010;<lpage>1379</lpage>.<pub-id pub-id-type="pmid">11100123</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0066"><label>66</label><mixed-citation publication-type="journal" id="rmv2143-cit-0066">
<string-name>
<surname>Pruijssers</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Denison</surname>
<given-names>MR</given-names>
</string-name>. <article-title>Nucleoside analogues for the treatment of coronavirus infections</article-title>. <source xml:lang="en">Curr Opin Virol</source>. <year>2019</year>;<volume>35</volume>:<fpage>57</fpage>&#x02010;<lpage>62</lpage>.<pub-id pub-id-type="pmid">31125806</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0067"><label>67</label><mixed-citation publication-type="journal" id="rmv2143-cit-0067">
<string-name>
<surname>Feld</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Hoofnagle</surname>
<given-names>JH</given-names>
</string-name>. <article-title>Mechanism of action of interferon and ribavirin in treatment of hepatitis C</article-title>. <source xml:lang="en">Nature</source>. <year>2005</year>;<volume>436</volume>(<issue>7053</issue>):<fpage>967</fpage>&#x02010;<lpage>972</lpage>.<pub-id pub-id-type="pmid">16107837</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0068"><label>68</label><mixed-citation publication-type="journal" id="rmv2143-cit-0068">
<string-name>
<surname>Ferron</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Subissi</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Silveira De Morais</surname>
<given-names>AT</given-names>
</string-name>, et al. <article-title>Structural and molecular basis of mismatch correction and ribavirin excision from coronavirus RNA</article-title>. <source xml:lang="en">Proc Natl Acad Sci U S A</source>. <year>2018</year>;<volume>115</volume>(<issue>2</issue>):<fpage>E162</fpage>&#x02010;<lpage>E171</lpage>.<pub-id pub-id-type="pmid">29279395</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0069"><label>69</label><mixed-citation publication-type="journal" id="rmv2143-cit-0069">
<string-name>
<surname>Smith</surname>
<given-names>EC</given-names>
</string-name>, <string-name>
<surname>Blanc</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Surdel</surname>
<given-names>MC</given-names>
</string-name>, <string-name>
<surname>Vignuzzi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Denison</surname>
<given-names>MR</given-names>
</string-name>. <article-title>Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutics</article-title>. <source xml:lang="en">PLoS Pathog</source>. <year>2013</year>;<volume>9</volume>(<issue>8</issue>):<elocation-id>e1003565</elocation-id>.<pub-id pub-id-type="pmid">23966862</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0070"><label>70</label><mixed-citation publication-type="journal" id="rmv2143-cit-0070">
<string-name>
<surname>Str&#x000f6;her</surname>
<given-names>U</given-names>
</string-name>, <string-name>
<surname>DiCaro</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>Y</given-names>
</string-name>, et al. <article-title>Severe acute respiratory syndrome&#x02013;related coronavirus is inhibited by interferon&#x02010;&#x003b1;</article-title>. <source xml:lang="en">J Infect Dis</source>. <year>2004</year>;<volume>189</volume>(<issue>7</issue>):<fpage>1164</fpage>&#x02010;<lpage>1167</lpage>.<pub-id pub-id-type="pmid">15031783</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0071"><label>71</label><mixed-citation publication-type="journal" id="rmv2143-cit-0071">
<string-name>
<surname>Sheahan</surname>
<given-names>TP</given-names>
</string-name>, <string-name>
<surname>Sims</surname>
<given-names>AC</given-names>
</string-name>, <string-name>
<surname>Graham</surname>
<given-names>RL</given-names>
</string-name>, et al. <article-title>Broad&#x02010;spectrum antiviral GS&#x02010;5734 inhibits both epidemic and zoonotic coronaviruses</article-title>. <source xml:lang="en">Sci Transl Med</source>. <year>2017</year>;<volume>9</volume>(<issue>396</issue>):<elocation-id>eaal3653</elocation-id>.<pub-id pub-id-type="pmid">28659436</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0072"><label>72</label><mixed-citation publication-type="journal" id="rmv2143-cit-0072">
<string-name>
<surname>Sheahan</surname>
<given-names>TP</given-names>
</string-name>, <string-name>
<surname>Sims</surname>
<given-names>AC</given-names>
</string-name>, <string-name>
<surname>Leist</surname>
<given-names>SR</given-names>
</string-name>, et al. <article-title>Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS&#x02010;CoV</article-title>. <source xml:lang="en">Nat Commun</source>. <year>2020</year>;<volume>11</volume>(<issue>1</issue>):<fpage>222</fpage>.<pub-id pub-id-type="pmid">31924756</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0073"><label>73</label><mixed-citation publication-type="journal" id="rmv2143-cit-0073">
<string-name>
<surname>Furuta</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Takahashi</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Fukuda</surname>
<given-names>Y</given-names>
</string-name>, et al. <article-title>In vitro and in vivo activities of anti&#x02010;influenza virus compound T&#x02010;705</article-title>. <source xml:lang="en">Antimicrob Agents Chemother</source>. <year>2002</year>;<volume>46</volume>(<issue>4</issue>):<fpage>977</fpage>&#x02010;<lpage>981</lpage>.<pub-id pub-id-type="pmid">11897578</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0074"><label>74</label><mixed-citation publication-type="journal" id="rmv2143-cit-0074">
<string-name>
<surname>Kim</surname>
<given-names>J&#x02010;A</given-names>
</string-name>, <string-name>
<surname>Seong</surname>
<given-names>R&#x02010;K</given-names>
</string-name>, <string-name>
<surname>Kumar</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Shin</surname>
<given-names>OS</given-names>
</string-name>. <article-title>Favipiravir and ribavirin inhibit replication of Asian and African strains of Zika virus in different cell models</article-title>. <source xml:lang="en">Viruses</source>. <year>2018</year>;<volume>10</volume>(<issue>2</issue>):<fpage>72</fpage>.</mixed-citation></ref><ref id="rmv2143-bib-0075"><label>75</label><mixed-citation publication-type="journal" id="rmv2143-cit-0075">
<string-name>
<surname>Zmurko</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Marques</surname>
<given-names>RE</given-names>
</string-name>, <string-name>
<surname>Schols</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Verbeken</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>SJF</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Neyts</surname>
<given-names>J</given-names>
</string-name>. <article-title>The viral polymerase inhibitor 7&#x02010;deaza&#x02010;2&#x02019;&#x02010;C&#x02010;methyladenosine is a potent inhibitor of in vitro Zika virus replication and delays disease progression in a robust mouse infection model</article-title>. <source xml:lang="en">PLoS Negl Trop Dis</source>. <year>2016</year>;<volume>10</volume>(<issue>5</issue>):<elocation-id>e0004695</elocation-id>.<pub-id pub-id-type="pmid">27163257</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0076"><label>76</label><mixed-citation publication-type="journal" id="rmv2143-cit-0076">
<string-name>
<surname>Delang</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Segura Guerrero</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Tas</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Mutations in the chikungunya virus non&#x02010;structural proteins cause resistance to favipiravir (T&#x02010;705), a broad&#x02010;spectrum antiviral</article-title>. <source xml:lang="en">J Antimicrob Chemother</source>. <year>2014</year>;<volume>69</volume>(<issue>10</issue>):<fpage>2770</fpage>&#x02010;<lpage>2784</lpage>.<pub-id pub-id-type="pmid">24951535</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0077"><label>77</label><mixed-citation publication-type="journal" id="rmv2143-cit-0077">
<string-name>
<surname>Rocha&#x02010;Pereira</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Jochmans</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Dallmeier</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Leyssen</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Nascimento</surname>
<given-names>MSJ</given-names>
</string-name>, <string-name>
<surname>Neyts</surname>
<given-names>J</given-names>
</string-name>. <article-title>Favipiravir (T&#x02010;705) inhibits in vitro norovirus replication</article-title>. <source xml:lang="en">Biochem Biophys Res Commun</source>. <year>2012</year>;<volume>424</volume>(<issue>4</issue>):<fpage>777</fpage>&#x02010;<lpage>780</lpage>.<pub-id pub-id-type="pmid">22809499</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0078"><label>78</label><mixed-citation publication-type="journal" id="rmv2143-cit-0078">
<string-name>
<surname>Guedj</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Piorkowski</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Jacquot</surname>
<given-names>F</given-names>
</string-name>, et al. <article-title>Antiviral efficacy of favipiravir against Ebola virus: a translational study in cynomolgus macaques</article-title>. <source xml:lang="en">PLoS Med.</source>
<year>2018</year>;<volume>15</volume>(<issue>3</issue>):<elocation-id>e1002535</elocation-id>.<pub-id pub-id-type="pmid">29584730</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0079"><label>79</label><mixed-citation publication-type="journal" id="rmv2143-cit-0079">
<string-name>
<surname>Oestereich</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>L&#x000fc;dtke</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Wurr</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Rieger</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Mu&#x000f1;oz&#x02010;Fontela</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>G&#x000fc;nther</surname>
<given-names>S</given-names>
</string-name>. <article-title>Successful treatment of advanced Ebola virus infection with T&#x02010;705 (favipiravir) in a small animal model</article-title>. <source xml:lang="en">Antiviral Res</source>. <year>2014</year>;<volume>105</volume>:<fpage>17</fpage>&#x02010;<lpage>21</lpage>.<pub-id pub-id-type="pmid">24583123</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0080"><label>80</label><mixed-citation publication-type="journal" id="rmv2143-cit-0080">
<string-name>
<surname>Smither</surname>
<given-names>SJ</given-names>
</string-name>, <string-name>
<surname>Eastaugh</surname>
<given-names>LS</given-names>
</string-name>, <string-name>
<surname>Steward</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Nelson</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Lenk</surname>
<given-names>RP</given-names>
</string-name>, <string-name>
<surname>Lever</surname>
<given-names>MS</given-names>
</string-name>. <article-title>Post&#x02010;exposure efficacy of oral T&#x02010;705 (favipiravir) against inhalational Ebola virus infection in a mouse model</article-title>. <source xml:lang="en">Antiviral Res</source>. <year>2014</year>;<volume>104</volume>:<fpage>153</fpage>&#x02010;<lpage>155</lpage>.<pub-id pub-id-type="pmid">24462697</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0081"><label>81</label><mixed-citation publication-type="miscellaneous" id="rmv2143-cit-0081">
<collab collab-type="authors">Shannon A, Selisko B, Le TTN</collab>
, et al. <article-title>Favipiravir strikes the SARS&#x02010;CoV&#x02010;2 at its Achilles heel, the RNA polymerase. Nature Com</article-title>, in press. 2020.</mixed-citation></ref><ref id="rmv2143-bib-0082"><label>82</label><mixed-citation publication-type="miscellaneous" id="rmv2143-cit-0082">
<string-name>
<surname>Jeon</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Ko</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>J</given-names>
</string-name>, et al. Identification of antiviral drug candidates against SARS&#x02010;CoV&#x02010;2 from FDA&#x02010;approved drugs. bioRxiv. 2020. <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2020.03.20.999730v3">https://www.biorxiv.org/content/10.1101/2020.03.20.999730v3</ext-link>. Accessed April 27, 2020.</mixed-citation></ref><ref id="rmv2143-bib-0083"><label>83</label><mixed-citation publication-type="journal" id="rmv2143-cit-0083">
<string-name>
<surname>Cinatl</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Morgenstern</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Bauer</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Chandra</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Rabenau</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Doerr</surname>
<given-names>HW</given-names>
</string-name>. <article-title>Treatment of SARS with human interferons</article-title>. <source xml:lang="en">Lancet</source>. <year>2003</year>;<volume>362</volume>(<issue>9380</issue>):<fpage>293</fpage>&#x02010;<lpage>294</lpage>.<pub-id pub-id-type="pmid">12892961</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0084"><label>84</label><mixed-citation publication-type="journal" id="rmv2143-cit-0084">
<string-name>
<surname>Hensley</surname>
<given-names>LE</given-names>
</string-name>, <string-name>
<surname>Fritz</surname>
<given-names>EA</given-names>
</string-name>, <string-name>
<surname>Jahrling</surname>
<given-names>PB</given-names>
</string-name>, <string-name>
<surname>Karp</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Huggins</surname>
<given-names>JW</given-names>
</string-name>, <string-name>
<surname>Geisbert</surname>
<given-names>TW</given-names>
</string-name>. <article-title>Interferon&#x02010;&#x003b2; 1a and SARS coronavirus replication</article-title>. <source xml:lang="en">Emerg Infect Dis</source>. <year>2004</year>;<volume>10</volume>(<issue>2</issue>):<fpage>317</fpage>&#x02010;<lpage>319</lpage>.<pub-id pub-id-type="pmid">15030704</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0085"><label>85</label><mixed-citation publication-type="journal" id="rmv2143-cit-0085">
<string-name>
<surname>Paragas</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Blatt</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Hartmann</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Huggins</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Endy</surname>
<given-names>T</given-names>
</string-name>. <article-title>Interferon alfacon1 is an inhibitor of SARS&#x02010;corona virus in cell&#x02010;based models</article-title>. <source xml:lang="en">Antiviral Res</source>. <year>2005</year>;<volume>66</volume>(<issue>2&#x02010;3</issue>):<fpage>99</fpage>&#x02010;<lpage>102</lpage>.<pub-id pub-id-type="pmid">15911026</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0086"><label>86</label><mixed-citation publication-type="journal" id="rmv2143-cit-0086">
<string-name>
<surname>Totura</surname>
<given-names>AL</given-names>
</string-name>, <string-name>
<surname>Whitmore</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Agnihothram</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>Toll&#x02010;like receptor 3 signaling via TRIF contributes to a protective innate immune response to severe acute respiratory syndrome coronavirus infection</article-title>. <source xml:lang="en">MBio</source>. <year>2015</year>;<volume>6</volume>(<issue>3</issue>):<elocation-id>e00638&#x02010;15</elocation-id>.<pub-id pub-id-type="pmid">26015500</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0087"><label>87</label><mixed-citation publication-type="journal" id="rmv2143-cit-0087">
<string-name>
<surname>Ziegler</surname>
<given-names>CGK</given-names>
</string-name>, <string-name>
<surname>Allon</surname>
<given-names>SJ</given-names>
</string-name>, <string-name>
<surname>Nyquist</surname>
<given-names>SK</given-names>
</string-name>, et al. <article-title>SARS&#x02010;CoV&#x02010;2 receptor ACE2 is an interferon&#x02010;stimulated gene in human airway epithelial cells and is detected in specific cell subsets across tissues</article-title>. <source xml:lang="en">Cell</source>. <year>2020</year>;<volume>181</volume>:<fpage>1016</fpage>&#x02013;<lpage>1035</lpage>. <pub-id pub-id-type="pmid">32413319</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0088"><label>88</label><mixed-citation publication-type="journal" id="rmv2143-cit-0088">
<string-name>
<surname>Zhang</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>J&#x02010;W</given-names>
</string-name>, <string-name>
<surname>Zhao</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>GQ</given-names>
</string-name>. <article-title>The cytokine release syndrome (CRS) of severe COVID&#x02010;19 and Interleukin&#x02010;6 receptor (IL&#x02010;6R) antagonist Tocilizumab may be the key to reduce the mortality</article-title>. <source xml:lang="en">Int J Antimicrob Agents</source>. <year>2020</year>;<volume>55</volume>:<elocation-id>105954</elocation-id>
<pub-id pub-id-type="pmid">32234467</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0089"><label>89</label><mixed-citation publication-type="journal" id="rmv2143-cit-0089">
<string-name>
<surname>Conti</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Gallenga</surname>
<given-names>CE</given-names>
</string-name>, <string-name>
<surname>Tet&#x000e8;</surname>
<given-names>G</given-names>
</string-name>, et al. <article-title>How to reduce the likelihood of coronavirus&#x02010;19 (CoV&#x02010;19 or SARS&#x02010;CoV&#x02010;2) infection and lung inflammation mediated by IL&#x02010;1</article-title>. <source xml:lang="en">J Biol Regul Homeost Agents</source>. <year>2020</year>;<volume>34</volume>(<issue>2</issue>):<fpage>11</fpage>&#x02013;<lpage>16</lpage>. </mixed-citation></ref><ref id="rmv2143-bib-0090"><label>90</label><mixed-citation publication-type="journal" id="rmv2143-cit-0090">
<string-name>
<surname>Conti</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Ronconi</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Caraffa</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Induction of pro&#x02010;inflammatory cytokines (IL&#x02010;1 and IL&#x02010;6) and lung inflammation by Coronavirus&#x02010;19 (COVI&#x02010;19 or SARS&#x02010;CoV&#x02010;2): anti&#x02010;inflammatory strategies</article-title>. <source xml:lang="en">J Biol Regul Homeost Agents</source>. <year>2020</year>;<volume>34</volume>(<issue>2</issue>).</mixed-citation></ref><ref id="rmv2143-bib-0091"><label>91</label><mixed-citation publication-type="journal" id="rmv2143-cit-0091">
<string-name>
<surname>Ledford</surname>
<given-names>H</given-names>
</string-name>. <article-title>Coronavirus breakthrough: dexamethasone is first drug shown to save lives</article-title>. <source xml:lang="en">Nature</source>. <year>2020</year>;<volume>582</volume>:<fpage>469</fpage>
<pub-id pub-id-type="pmid">32546811</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0092"><label>92</label><mixed-citation publication-type="miscellaneous" id="rmv2143-cit-0092">
<string-name>
<surname>Hoffmann</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Schroeder</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kleine&#x02010;Weber</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>M&#x000fc;ller</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Drosten</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>P&#x000f6;hlmann</surname>
<given-names>S</given-names>
</string-name>. Nafamostat Mesylate Blocks Activation of SARS&#x02010;CoV&#x02010;2: New Treatment Option. The Currently Unfolding Coronavirus Pandemic Threatens Health Systems and Economies. 2020. <ext-link ext-link-type="uri" xlink:href="http://aac.asm.org/">http://aac.asm.org/</ext-link>. Accessed April 27, 2020.</mixed-citation></ref><ref id="rmv2143-bib-0093"><label>93</label><mixed-citation publication-type="journal" id="rmv2143-cit-0093">
<string-name>
<surname>Vincent</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Bergeron</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Benjannet</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>Chloroquine is a potent inhibitor of SARS coronavirus infection and spread</article-title>. <source xml:lang="en">Virol J</source>. <year>2005</year>;<volume>2</volume>(<issue>1</issue>):<fpage>69</fpage>.<pub-id pub-id-type="pmid">16115318</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0094"><label>94</label><mixed-citation publication-type="journal" id="rmv2143-cit-0094">
<string-name>
<surname>Keyaerts</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Vijgen</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Maes</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Neyts</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Van Ranst</surname>
<given-names>M</given-names>
</string-name>. <article-title>In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine</article-title>. <source xml:lang="en">Biochem Biophys Res Commun</source>. <year>2004</year>;<volume>323</volume>(<issue>1</issue>):<fpage>264</fpage>&#x02010;<lpage>268</lpage>.<pub-id pub-id-type="pmid">15351731</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0095"><label>95</label><mixed-citation publication-type="journal" id="rmv2143-cit-0095">
<string-name>
<surname>Yao</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Ye</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS&#x02010;CoV&#x02010;2)</article-title>. <source xml:lang="en">Clin Infect Dis</source>. <year>2020</year>. [Online ahead of print].</mixed-citation></ref><ref id="rmv2143-bib-0096"><label>96</label><mixed-citation publication-type="journal" id="rmv2143-cit-0096">
<string-name>
<surname>Liu</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Cao</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Xu</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS&#x02010;CoV&#x02010;2 infection in vitro</article-title>. <source xml:lang="en">Cell Discov</source>. <year>2020</year>;<volume>6</volume>(<issue>1</issue>):<fpage>16</fpage>.<pub-id pub-id-type="pmid">32194981</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0097"><label>97</label><mixed-citation publication-type="journal" id="rmv2143-cit-0097">
<string-name>
<surname>Gao</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Tian</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Yang</surname>
<given-names>X</given-names>
</string-name>. <article-title>Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID&#x02010;19 associated pneumonia in clinical studies</article-title>. <source xml:lang="en">Biosci Trends</source>. <year>2020</year>;<volume>14</volume>(<issue>1</issue>):<fpage>72</fpage>&#x02010;<lpage>73</lpage>.<pub-id pub-id-type="pmid">32074550</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0098"><label>98</label><mixed-citation publication-type="journal" id="rmv2143-cit-0098">
<string-name>
<surname>Gautret</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Lagier</surname>
<given-names>J&#x02010;C</given-names>
</string-name>, <string-name>
<surname>Parola</surname>
<given-names>P</given-names>
</string-name>, et al. <article-title>Hydroxychloroquine and azithromycin as a treatment of COVID&#x02010;19: results of an open&#x02010;label non&#x02010;randomized clinical trial</article-title>. <source xml:lang="en">Int J Antimicrob Agents</source>. <year>2020</year>;<elocation-id>105949</elocation-id>.<pub-id pub-id-type="pmid">32205204</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0099"><label>99</label><mixed-citation publication-type="journal" id="rmv2143-cit-0099">
<string-name>
<surname>Caly</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Druce</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>Catton</surname>
<given-names>MG</given-names>
</string-name>, <string-name>
<surname>Jans</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Wagstaff</surname>
<given-names>KM</given-names>
</string-name>. <article-title>The FDA&#x02010;approved Drug Ivermectin inhibits the replication of SARS&#x02010;CoV&#x02010;2 in vitro</article-title>. <source xml:lang="en">Antiviral Res</source>. <year>2020</year>;<volume>178</volume>:<elocation-id>104787</elocation-id>
<pub-id pub-id-type="pmid">32251768</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0100"><label>100</label><mixed-citation publication-type="journal" id="rmv2143-cit-0100">
<string-name>
<surname>Kuster</surname>
<given-names>GM</given-names>
</string-name>, <string-name>
<surname>Pfister</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Burkard</surname>
<given-names>T</given-names>
</string-name>, et al. <article-title>SARS&#x02010;CoV2: should inhibitors of the renin&#x02013;angiotensin system be withdrawn in patients with COVID&#x02010;19?</article-title>
<source xml:lang="en">Eur Heart J</source>. <year>2020</year>;<volume>41</volume>:<fpage>1801</fpage>&#x02013;<lpage>1803</lpage>. <pub-id pub-id-type="pmid">32196087</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0101"><label>101</label><mixed-citation publication-type="journal" id="rmv2143-cit-0101">
<string-name>
<surname>Meng</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Xiao</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Renin&#x02010;angiotensin system inhibitors improve the clinical outcomes of COVID&#x02010;19 patients with hypertension</article-title>. <source xml:lang="en">Emerg Microbes Infect</source>. <year>2020</year>;<volume>9</volume>(<issue>1</issue>):<fpage>757</fpage>&#x02010;<lpage>760</lpage>.<pub-id pub-id-type="pmid">32228222</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0102"><label>102</label><mixed-citation publication-type="journal" id="rmv2143-cit-0102">
<string-name>
<surname>Sukumaran</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Tsuchimochi</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Tatsumi</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Shirai</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Pearson</surname>
<given-names>JT</given-names>
</string-name>. <article-title>Azilsartan ameliorates diabetic cardiomyopathy in young db/db mice through the modulation of ACE&#x02010;2/ANG 1&#x02013;7/Mas receptor cascade</article-title>. <source xml:lang="en">Biochem Pharmacol</source>. <year>2017</year>;<volume>144</volume>:<fpage>90</fpage>&#x02010;<lpage>99</lpage>.<pub-id pub-id-type="pmid">28789938</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0103"><label>103</label><mixed-citation publication-type="journal" id="rmv2143-cit-0103">
<string-name>
<surname>Fosb&#x000f8;l</surname>
<given-names>EL</given-names>
</string-name>, <string-name>
<surname>Butt</surname>
<given-names>JH</given-names>
</string-name>, <string-name>
<surname>&#x000d8;stergaard</surname>
<given-names>L</given-names>
</string-name>, et al. <article-title>Association of angiotensin&#x02010;converting enzyme inhibitor or angiotensin receptor blocker use with COVID&#x02010;19 diagnosis and mortality</article-title>. <source xml:lang="en">JAMA</source>. <year>2020</year>;<volume>126</volume>:<fpage>1671</fpage>&#x02013;<lpage>1681</lpage>. </mixed-citation></ref><ref id="rmv2143-bib-0104"><label>104</label><mixed-citation publication-type="journal" id="rmv2143-cit-0104">
<string-name>
<surname>Hoffmann</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Schroeder</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kleine&#x02010;Weber</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>M&#x000fc;ller</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Drosten</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>P&#x000f6;hlmann</surname>
<given-names>S</given-names>
</string-name>. <article-title>Nafamostat mesylate blocks activation of SARS&#x02010;CoV&#x02010;2: new treatment option for COVID&#x02010;19</article-title>. <source xml:lang="en">Antimicrob Agents Chemother</source>. <year>2020</year>;<volume>64</volume>:<fpage>754</fpage>&#x02013;<lpage>820</lpage>. </mixed-citation></ref><ref id="rmv2143-bib-0105"><label>105</label><mixed-citation publication-type="journal" id="rmv2143-cit-0105">
<string-name>
<surname>Hoffmann</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kleine&#x02010;Weber</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Schroeder</surname>
<given-names>S</given-names>
</string-name>, et al. <article-title>SARS&#x02010;CoV&#x02010;2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor</article-title>. <source xml:lang="en">Cell</source>. <year>2020</year>;<volume>181</volume>:<fpage>271</fpage>&#x02013;<lpage>280</lpage>. <pub-id pub-id-type="pmid">32142651</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0106"><label>106</label><mixed-citation publication-type="journal" id="rmv2143-cit-0106">
<string-name>
<surname>Savarino</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Boelaert</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Cassone</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Majori</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Cauda</surname>
<given-names>R</given-names>
</string-name>. <article-title>Effects of chloroquine on viral infections: an old drug against today's diseases</article-title>. <source xml:lang="en">Lancet Infect Dis</source>. <year>2003</year>;<volume>3</volume>(<issue>11</issue>):<fpage>722</fpage>&#x02010;<lpage>727</lpage>.<pub-id pub-id-type="pmid">14592603</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0107"><label>107</label><mixed-citation publication-type="journal" id="rmv2143-cit-0107">
<string-name>
<surname>Pantoliano</surname>
<given-names>MW</given-names>
</string-name>, <string-name>
<surname>Petrella</surname>
<given-names>EC</given-names>
</string-name>, <string-name>
<surname>Kwasnoski</surname>
<given-names>JD</given-names>
</string-name>, et al. <article-title>High&#x02010;density miniaturized thermal shift assays as a general strategy for drug discovery</article-title>. <source xml:lang="en">J Biomol Screen</source>. <year>2001</year>;<volume>6</volume>(<issue>6</issue>):<fpage>429</fpage>&#x02010;<lpage>440</lpage>.<pub-id pub-id-type="pmid">11788061</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0108"><label>108</label><mixed-citation publication-type="journal" id="rmv2143-cit-0108">
<collab collab-type="authors">Tripathy S, Dassarma B, Roy S, Chabalala H, Matsabisa MG.</collab>
<article-title>A review on possible modes of action of chloroquine/hydroxychloroquine: repurposing against SAR&#x02010;CoV&#x02010;2 (COVID&#x02010;19) pandemic.</article-title>
<source xml:lang="en">Int J Antimicrob Agents</source>. <year>2020</year>;<elocation-id>106028</elocation-id>
<ext-link ext-link-type="uri" xlink:href="http://dx.doi/10.1016/j.ijantimicag.2020.106028">http://dx.doi/10.1016/j.ijantimicag.2020.106028</ext-link>
<pub-id pub-id-type="pmid">32450198</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0109"><label>109</label><mixed-citation publication-type="journal" id="rmv2143-cit-0109">
<string-name>
<surname>Schrezenmeier</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>D&#x000f6;rner</surname>
<given-names>T</given-names>
</string-name>. <article-title>Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology</article-title>. <source xml:lang="en">Nat Rev Rheumatol</source>. <year>2020</year>;<volume>16</volume>(<issue>3</issue>):<fpage>155</fpage>&#x02010;<lpage>166</lpage>.<pub-id pub-id-type="pmid">32034323</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0110"><label>110</label><mixed-citation publication-type="miscellaneous" id="rmv2143-cit-0110">Statement on IJAA Paper. International Society of Antimicrobial Chemotherapy. <ext-link ext-link-type="uri" xlink:href="https://www.isac.world/news-and-publications/official-isac-statement">https://www.isac.world/news-and-publications/official-isac-statement</ext-link>. Accessed April 30, 2020.</mixed-citation></ref><ref id="rmv2143-bib-0111"><label>111</label><mixed-citation publication-type="journal" id="rmv2143-cit-0111">
<string-name>
<surname>Gielen</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Johnston</surname>
<given-names>SL</given-names>
</string-name>, <string-name>
<surname>Edwards</surname>
<given-names>MR</given-names>
</string-name>. <article-title>Azithromycin induces anti&#x02010;viral responses in bronchial epithelial cells</article-title>. <source xml:lang="en">Eur Respir J</source>. <year>2010</year>;<volume>36</volume>(<issue>3</issue>):<fpage>646</fpage>&#x02010;<lpage>654</lpage>.<pub-id pub-id-type="pmid">20150207</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0112"><label>112</label><mixed-citation publication-type="miscellaneous" id="rmv2143-cit-0112">
<string-name>
<surname>Deretic</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Timmins</surname>
<given-names>GS</given-names>
</string-name>. Azithromycin and ciprofloxacin have a chloroquine&#x02010;like effect on respiratory epithelial cells. bioRxiv. 2020. <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2020.03.29.008631v1">https://www.biorxiv.org/content/10.1101/2020.03.29.008631v1</ext-link>. Accessed April 5, 2020.</mixed-citation></ref><ref id="rmv2143-bib-0113"><label>113</label><mixed-citation publication-type="journal" id="rmv2143-cit-0113">
<string-name>
<surname>Pani</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Lauriola</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Romandini</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Scaglione</surname>
<given-names>F</given-names>
</string-name>. <article-title>Macrolides and viral infections: focus on azithromycin in COVID&#x02010;19 pathology</article-title>. <source xml:lang="en">Int J Antimicrob Agents</source>. <year>2020</year>;<elocation-id>106053</elocation-id>.<pub-id pub-id-type="pmid">32534189</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0114"><label>114</label><mixed-citation publication-type="journal" id="rmv2143-cit-0114">
<string-name>
<surname>Aghai</surname>
<given-names>ZH</given-names>
</string-name>, <string-name>
<surname>Kode</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Saslow</surname>
<given-names>JG</given-names>
</string-name>, et al. <article-title>Azithromycin suppresses activation of nuclear factor&#x02010;kappa B and synthesis of pro&#x02010;inflammatory cytokines in tracheal aspirate cells from premature infants</article-title>. <source xml:lang="en">Pediatr Res</source>. <year>2007</year>;<volume>62</volume>(<issue>4</issue>):<fpage>483</fpage>&#x02010;<lpage>488</lpage>.<pub-id pub-id-type="pmid">17667842</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0115"><label>115</label><mixed-citation publication-type="journal" id="rmv2143-cit-0115">
<string-name>
<surname>Taylor</surname>
<given-names>SP</given-names>
</string-name>, <string-name>
<surname>Sellers</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Taylor</surname>
<given-names>BT</given-names>
</string-name>. <article-title>Azithromycin for the prevention of COPD exacerbations: the good, bad, and ugly</article-title>. <source xml:lang="en">Am J Med</source>. <year>2015</year>;<volume>128</volume>(<issue>12</issue>):<fpage>1362</fpage>.</mixed-citation></ref><ref id="rmv2143-bib-0116"><label>116</label><mixed-citation publication-type="journal" id="rmv2143-cit-0116">
<string-name>
<surname>Bouwman</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Visseren</surname>
<given-names>FL</given-names>
</string-name>, <string-name>
<surname>Bouter</surname>
<given-names>PK</given-names>
</string-name>, <string-name>
<surname>Diepersloot</surname>
<given-names>RJ</given-names>
</string-name>. <article-title>Azithromycin inhibits interleukin&#x02010;6 but not fibrinogen production in hepatocytes infected with cytomegalovirus and chlamydia pneumoniae</article-title>. <source xml:lang="en">J Lab Clin Med</source>. <year>2004</year>;<volume>144</volume>(<issue>1</issue>):<fpage>18</fpage>&#x02010;<lpage>26</lpage>.<pub-id pub-id-type="pmid">15252403</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0117"><label>117</label><mixed-citation publication-type="journal" id="rmv2143-cit-0117">
<string-name>
<surname>Ulrich</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Pillat</surname>
<given-names>MM</given-names>
</string-name>. <article-title>CD147 as a target for COVID&#x02010;19 treatment: suggested effects of azithromycin and stem cell engagement</article-title>. <source xml:lang="en">Stem Cell Rev Reports</source>. <year>2020</year>;<volume>16</volume>:<fpage>434</fpage>&#x02013;<lpage>440</lpage>.</mixed-citation></ref><ref id="rmv2143-bib-0118"><label>118</label><mixed-citation publication-type="journal" id="rmv2143-cit-0118">
<string-name>
<surname>Wagstaff</surname>
<given-names>KM</given-names>
</string-name>, <string-name>
<surname>Sivakumaran</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Heaton</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Harrich</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Jans</surname>
<given-names>DA</given-names>
</string-name>. <article-title>Ivermectin is a specific inhibitor of importin &#x003b1;/&#x003b2;&#x02010;mediated nuclear import able to inhibit replication of HIV&#x02010;1 and dengue virus</article-title>. <source xml:lang="en">Biochem J</source>. <year>2012</year>;<volume>443</volume>(<issue>3</issue>):<fpage>851</fpage>&#x02010;<lpage>856</lpage>.<pub-id pub-id-type="pmid">22417684</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0119"><label>119</label><mixed-citation publication-type="journal" id="rmv2143-cit-0119">
<string-name>
<surname>Lundberg</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Pinkham</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Baer</surname>
<given-names>A</given-names>
</string-name>, et al. <article-title>Nuclear import and export inhibitors alter capsid protein distribution in mammalian cells and reduce Venezuelan Equine Encephalitis Virus replication</article-title>. <source xml:lang="en">Antiviral Res</source>. <year>2013</year>;<volume>100</volume>(<issue>3</issue>):<fpage>662</fpage>&#x02010;<lpage>672</lpage>.<pub-id pub-id-type="pmid">24161512</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0120"><label>120</label><mixed-citation publication-type="journal" id="rmv2143-cit-0120">
<string-name>
<surname>Tay</surname>
<given-names>MYF</given-names>
</string-name>, <string-name>
<surname>Fraser</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Chan</surname>
<given-names>WKK</given-names>
</string-name>, et al. <article-title>Nuclear localization of dengue virus (DENV) 1&#x02013;4 non&#x02010;structural protein 5; protection against all 4 DENV serotypes by the inhibitor Ivermectin</article-title>. <source xml:lang="en">Antiviral Res</source>. <year>2013</year>;<volume>99</volume>(<issue>3</issue>):<fpage>301</fpage>&#x02010;<lpage>306</lpage>.<pub-id pub-id-type="pmid">23769930</pub-id></mixed-citation></ref><ref id="rmv2143-bib-0121"><label>121</label><mixed-citation publication-type="miscellaneous" id="rmv2143-cit-0121">
<string-name>
<surname>Patel</surname>
<given-names>A</given-names>
</string-name>. Usefulness of Ivermectin in COVID&#x02010;19 Illness. 2020. <ext-link ext-link-type="uri" xlink:href="https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3580524">https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3580524</ext-link>. Accessed April 27, 2020.</mixed-citation></ref><ref id="rmv2143-bib-0122"><label>122</label><mixed-citation publication-type="journal" id="rmv2143-cit-0122">
<string-name>
<surname>Momekov</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Momekova</surname>
<given-names>D</given-names>
</string-name>. <article-title>Ivermectin as a potential COVID&#x02010;19 treatment from the pharmacokinetic point of view: antiviral levels are not likely attainable with known dosing regimens</article-title>. <source xml:lang="en">Biotechnol Biotechnol Equip</source>. <year>2020</year>;<volume>34</volume>(<issue>1</issue>):<fpage>469</fpage>&#x02013;<lpage>474</lpage>. <pub-id pub-id-type="doi">10.1101/2020.04.11.20061804</pub-id>.</mixed-citation></ref><ref id="rmv2143-bib-0123"><label>123</label><mixed-citation publication-type="journal" id="rmv2143-cit-0123">
<string-name>
<surname>Gubareva</surname>
<given-names>LV</given-names>
</string-name>, <string-name>
<surname>Kaiser</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Hayden</surname>
<given-names>FG</given-names>
</string-name>. <article-title>Influenza virus neuraminidase inhibitors</article-title>. <source xml:lang="en">Lancet</source>. <year>2000</year>;<volume>355</volume>(<issue>9206</issue>):<fpage>827</fpage>&#x02010;<lpage>835</lpage>.<pub-id pub-id-type="pmid">10711940</pub-id></mixed-citation></ref></ref-list></back></article>